Zusammenfassung
Das Gelenkrheuma im Kindesalter umfasst eine heterogene Gruppe von Erkrankungen, deren gemeinsames Merkmal die chronische Gelenkentzündung unbekannter Ursache ist. Die Identifizierung dieser Erkrankung erfolgt, bei weitgehend unbekannter Ätiopathogenese und fehlenden pathognomonischen Krankheitsmerkmalen, anhand einer Kombination von klinischen, labormedizinischen und anderen Merkmalen.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
Literatur
Literatur zu Kap. 4.1
Brewer EJ, Bass J, Baum J et al. (1977) Current proposed revision of JRA criteria. Arthritis Rheum 20 (Suppl): 195–199
Fink CW, the Task Force for Classification Criteria (1995) Proposal for the development of classification criteria for idiopathic arthritides of childhood. J Rheumatol 22: 1566–1569
Nordal E, Zak M, Aalto K et al. (2011) Ongoing disease activity and changing categories in a long-term nordic cohort study of juvenile idiopathic arthritis. Arthritis Rheum 63:2809–18
Petty RE, Southwood TR, Baum J et al. (1998) Revision of the proposed classification criteria for juvenile idiopathic arthritis: Durban, 1997. J Rheumatol 25: 1991–1994
Petty RE, Southwood TR, Manners P et al. (2004) International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: Second revision, Edmonton, 2001. J Rheumatol 31: 390–392
Thomas E, Barrett JH, Donn RP, Thomson W, Southwood TR (2000) Subtyping of juvenile idiopathic arthritis using latent class analysis. British Paediatric Rheumatology Group. Arthritis Rheum 43: 1496–1503
Wood PHN (1978) Special meeting on: nomenclature and classification of arthritis in children. In: Munthe E (ed) The care of rheumatic children. EULAR, Basel, pp47–50
Literatur zu Kap. 4.2
Arkela-Kautiainen M, Haapasaari J, Kautiainen H, Vilkkumaa I, Malkia E, and Leirisalo-Repo M (2005) Favourable social functioning and health related quality of life of patients with JIA in early adulthood. Ann Rheum Dis 64:875–880
Berntson L, Andersson Gäre B, Fasth A et al. (2003) Incidence of juvenile idiopathic arthritis in the Nordic countries. A population based study with special reference to the validity of the ILAR and EULAR criteria. J Rheumatol 30: 2275–2282
Beukelman T, Haynes K, Curtis JR, Xie F, Chen L, Bemrich-Stolz CJ, Delzell E, Saag KG, Solomon DH, Lewis JD (2012) Safety Assessment of Biological Therapeutics Collaboration. Rates of malignancy associated with juvenile idiopathic arthritis and its treatment. Arthritis Rheum 64(4):1263–71
Danner S, Sordet C, Terzic J, Donato L, Velten M, Fischbach M, Sibilia J (2006) Epidemiology of juvenile idiopathic arthritis in Alsace, France. J Rheumatol 33(7):1377–81
Ellis JA, Munro JE, Ponsonby AL (2010) Possible environmental determinants of juvenile idiopathic arthritis. Rheumatology (Oxford) 49(3):411–25
Flato B, Lien G, Smerdel A, Vinje O, Dale K, Johnston V, Sorskaar D et al. (2003) Prognostic factors in juvenile rheumatoid arthritis: a casecontrol study revealing early predictors and outcome after 14.9 years. J Rheumatol 30:386–393
Hashkes PJ, Wright BM, Lauer MS, Worley SE, Tang AS, Roettcher PA, Bowyer SL (2010) Mortality outcomes in pediatric rheumatology in the US. Arthritis Rheum 62(2):599–608
Hyrich KL, Lal SD, Foster HE, Thornton J, Adib N, Baildam E, Gardner- Medwin J, Wedderburn LR, Chieng A, Davidson J, Thomson W (2010) Disease activity and disability in children with juvenile idiopathic arthritis one year following presentation to paediatric rheumatology. Results from the Childhood Arthritis Prospective Study. Rheumatology (Oxford) 49:116–22
Kaipiainen-Seppänen O, Savolainen A (2001) Changes in the incidence of juvenile rheumatoid arthritis in Finland. Rheumatology (Oxford) 40(8):928–32
Kiessling U, Döring E, Listing J, Meincke J, Schöntube M, Strangfeld A, Zink A (1998) Incidence and prevalence of juvenile chronic arthritis in East Berlin 1980–88. J Rheumatol 25: 1837–1843
Koskull S von, Truckenbrodt H, Holle R, Hormann A (2001) Incidence and prevalence of juvenile arthritis in an urban population of southern Germany: A prospective study. Ann Rheum Dis 60: 940–945
Magnani A, Pistorio A, Magni-Manzoni S, Falcone A, Lombardini G, Bandeira M, Rossi F et al. (2009) Achievement of a state of inactive disease at least once in the first 5 years predicts better outcome of patients with polyarticular juvenile idiopathic arthritis. J Rheumatol 36:628–634
Manners PJ, Diepeveen DA (1996) Prevalence of juvenile chronic arthritis in a population of 12-year-old children in urban Australia. Pediatrics 98: 84–90
Minden K, Niewerth M, Zink A, Seipelt E, Foeldvari I, Girschick H, Ganser G, Horneff G (2012) Long-term outcome of patients with JIA treated with etanercept, results of the biologic register JuMBO. Rheumatology (Oxford) 51(8):1407–15
Nielsen HE, Dorup J, Herlin T, Larsen K, Nielsen S, Pedersen FK (1999) Epidemiology of juvenile chronic arthritis: Risk dependent on sibship, parental income, and housing. J Rheumatol 26: 1600–1605
Nordal E, Zak M, Aalto K, Berntson L, Fasth A, Herlin T, Lahdenne P, Nielsen S, Straume B, Rygg M; Nordic Study Group of Pediatric Rheumatology (2011) Ongoing disease activity and changing categories in a long-term nordic cohort study of juvenile idiopathic arthritis. Arthritis Rheum 63(9):2809–18
Oen K, Duffy CM, Tse SM, Ramsey S, Ellsworth J, Chédeville G, Chetaille AL, Saint-Cyr C, Cabral DA, Spiegel LR, Schneider R, Lang B, Huber AM, Dancey P, Silverman E, Rosenberg AM, Cameron B, Johnson N, Dorval J, Scuccimarri R, Campillo S, Petty RE, Duffy KN, Boire G, Haddad E, Houghton K, Laxer R, Turvey SE, Miettunen P, Gross K, Guzman J, Benseler S, Feldman BM, Espinosa V, Yeung RS, Tucker L (2010) Early outcomes and improvement of patients with juvenile idiopathic arthritis enrolled in a Canadian multicenter inception cohort. Arthritis Care Res (Hoboken) 62:527–36
Oen K, Reed M, Malleson PN, Cabral DA, Petty RE, Rosenberg AM, and Cheang M (2003) Radiologic outcome and its relationship to functional disability in juvenile rheumatoid arthritis. J Rheumatol 30:832–840
Oen KG, Chang M (1996) Epidemiology of chronic arthritis in childhood. Semin Arthritis Rheum 26: 575–591
Peterson LS, Mason T, Nelson AM, O’Fallon WM, Gabriel SE (1996) Juvenile rheumatoid arthritis in Rochester, Minnesota 1960–93. Is the epidemiology changing? Arthritis Rheum 39: 1385–1390
Pohjankoski H, Kautiainen H, Korppi M, Savolainen A (2012). Simultaneous juvenile idiopathic arthritis and diabetes mellitus type 1 – a Finnish nationwide study. J Rheumatol 39(2):377–81
Prahalad S, Glass DN (2008) A comprehensive review of the genetics of juvenile idiopathic arthritis. Pediatr Rheumatol Online J 21: 6:11
Prieur AM, Le Gall E, Karman F, Edan C, Lasserre O, Goujard J (1987) Epidemiologic survey of juvenile chronic arthritis in France. Comparison of data obtained from two different regions. Clin Exp Rheumatol 5: 217–223
Pruunsild C, Uibo K, Liivamägi H, Tarraste S, Talvik T, Pelkonen P (2007) Incidence of juvenile idiopathic arthritis in children in Estonia: a prospective population-based study. Scand J Rheumatol 36(1):7–13
Radon K, Windstetter D, Poluda D, Häfner R, Thomas S, Michels H, von Mutius E (2010) Exposure to animals and risk of oligoarticular juvenile idiopathic arthritis: a multicenter case-control study. BMC Musculoskelet Disord 11:73
Thomas E, Symmons DP, Brewster DH, Black RJ, Macfarlane GJ (2003) National study of cause-specific mortality in rheumatoid arthritis, juvenile chronic arthritis, and other rheumatic conditions: a 20 year followup study. J Rheumatol 30(5):958–65
Woo P, Colbert RA (2009) An overview of genetics of paediatric rheumatic diseases. Best Pract Res Clin Rheumatol 23(5):589–97
Literatur zu Kap. 4.3
Baars RM, Atherton CI, Koopman HM, Bullinger M, Power M; DISABKIDS group (2005) The European DISABKIDS project: development of seven condition-specific modules to measure health related quality of life in children and adolescents. Health Qual Life Outcomes 13:3:70
Brunner HI, Klein-Gitelman MS, Miller MJ, Barron A, Baldwin N, Trombley M, Johnson AL, Kress A, Lovell DJ, Giannini EH (2005) Minimal clinically important differences of the childhood health assessment questionnaire. J Rheumatol 32(1):150–61
Brunner HI, Lovell DJ, Finck BK, Giannini EH () Preliminary definition of disease flare in juvenile rheumatoid arthritis. J Rheumatol 29(5):1058–64
Bullinger M, Schmidt S, Petersen C, and the DISABKIDS Group (2002) Assessing quality of life of children with chronic health conditions and disabilities: a European approach. Int J Rehabil Res 25:197–206
Consolaro A, Bracciolini G, Ruperto N, Pistorio A, Magni-Manzoni S, Malattia C, Pederzoli S, Davì S, Martini A, Ravelli A; Paediatric Rheumatology International Trials Organization (2012) Remission, minimal disease activity, and acceptable symptom state in juvenile idiopathic arthritis: Defining criteria based on the juvenile arthritis disease activity score. Arthritis Rheum 64(7):2366–74
Consolaro A, Ruperto N, Bazso A, Pistorio A, Magni-Manzoni S, Filocamo G, Malattia C, Viola S, Martini A, Ravelli A; Paediatric Rheumatology International Trials Organisation (2009) Development and validation of a composite disease activity score for juvenile idiopathic arthritis. Arthritis Rheum (Arthritis Care Res) 61(5):658–66
Consolaro A, Ruperto N, Pistorio A, Lattanzi B, Solari N, Galasso R, Pederzoli S, Varnier GC, Dolezalova P, Alessio M, Burgos-Vargas R, Vesely R, Martini A, Ravelli A; Paediatric Rheumatology International Trials Organisation (2011) Development and initial validation of composite parent- and child-centered disease assessment indices for juvenile idiopathic arthritis. Arthritis Care Res (Hoboken) 63(9):1262–70
Damasio MB, Malattia C, Tanturri de Horatio L, Mattiuz C, Pistorio A, Bracaglia C, Barbuti D, Boavida P, Juhan KL, Ording LS, Rosendahl K, Martini A, Magnano G, Tomà P (2012) MRI of the wrist in juvenile idiopathic arthritis: proposal of a paediatric synovitis score by a consensus of an international working group. Results of a multicentre reliability study. Pediatr Radiol [Epub ahead of print]
de Jager W, Hoppenreijs EP, Wulffraat NM, Wedderburn LR, Kuis W, Prakken BJ (2007) Blood and synovial fluid cytokine signatures in patients with juvenile idiopathic arthritis: a cross-sectional study. Ann Rheum Dis 66(5):589–98
Dempster H, Porepa M, Young N, Feldman BM (2001) The clinical meaning of functional outcome scores in children with juvenile arthritis. Arthritis Rheum 44(8):1768–74
Filocamo G, Consolaro A, Schiappapietra B, Dalprà S, Lattanzi B, Magni- Manzoni S, Ruperto N, Pistorio A, Pederzoli S, Civino A, Guseinova D, Masala E, Viola S, Martini A, Ravelli A (2011) A new approach to clinical care of juvenile idiopathic arthritis: the Juvenile Arthritis Multidimensional Assessment Report. J Rheumatol 38(5):938–53
Filocamo G, Schiappapietra B, Bertamino M, Pistorio A, Ruperto N, Magni-Manzoni S, Lanni S, Saad-Magalhaes C, Galasso R, Lattanzi B, Muratore V, Tani D, Martini A, Ravelli A (2010) A new short and simple health-related quality of life measurement for paediatric rheumatic diseases: initial validation in juvenile idiopathic arthritis. Rheumatology (Oxford) 49(7):1272–80
Filocamo G, Sztajnbok F, Cespedes-Cruz A, Magni-Manzoni S, Pistorio A, Viola S, Ruperto N, Buoncompagni A, Loy A, Martini A, Ravelli A (2007) Development and validation of a new short and simple measure of physical function for juvenile idiopathic arthritis. Arthritis Rheum 57(6):913–20
Foeldvari I, Ruperto N, Dressler F, Häfner R, Küster RM, Michels H, Minden K, Schauer-Petrowskaja C, Bullinger M, Landgraf JM, Huppertz HI; Paediatric Rheumatology International Trials Organisation (2001) The German version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ). Clin Exp Rheumatol 19(4 Suppl 23):S71–5
Gerss J, Roth J, Holzinger D, Ruperto N, Wittkowski H, Frosch M, Wulffraat N, Wedderburn L, Stanevicha V, Mihaylova D, Harjacek M, Len C, Toppino C, Masi M, Minden K, Saurenmann T, Uziel Y, Vesely R, Apaz MT, Kuester RM, Elorduy MJ, Burgos-Vargas R, Ioseliani M, Magni-Manzoni S, Unsal E, Anton J, Balogh Z, Hagelberg S, Mazur- Zielinska H, Tauber T, Martini A, Foell D; for the Paediatric Rheumatology International Trials Organization (PRINTO) (2012) Phagocyte- specific S100 proteins and high-sensitivity C reactive protein as biomarkers for a risk-adapted treatment to maintain remission in juvenile idiopathic arthritis: a comparative study. Ann Rheum Dis [Epub ahead of print]
Giannini EH, Ruperto N, Ravelli A et al. (1997) Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 40 (7):1202–1209
Graham TB, Laor T, Dardzinski BJ (2005) Quantitative magnetic resonance imaging of the hands and wrists of children with juvenile rheumatoid arthritis. J Rheumatol 32(9):1811–20
Jabs DA, Nussenblatt RB, Rosenbaum JT; Standardization of Uveitis Nomenclature (SUN) Working Group (2005) Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol 140(3):509–16
Magni-Manzoni S, Epis O, Ravelli A, Klersy C, Veisconti C, Lanni S, Muratore V, Sciré CA, Rossi S, Montecucco C (2009) Comparison of clinical versus ultrasound-determined synovitis in juvenile idiopathic arthritis.Arthritis Rheum 61(11):1497–504
Magni-Manzoni S, Ruperto N, Pistorio A, Sala E, Solari N, Palmisani E, Cugno C, Bozzola E, Martini A, Ravelli A (2008) Development and validation of a preliminary definition of minimal disease activity in patients with juvenile idiopathic arthritis. Arthritis Rheum 59(8):1120–7
Malattia C, Consolaro A, Pederzoli S, Madeo A, Pistorio A, Mazzoni M, Mattiuz C, Magnano G, Viola S, Buoncompagni A, Palmisani E, Hasija R, Ruperto N, Ravelli A, Martini A (2012) MRI versus conventional measures of disease activity and structural damage in evaluating treatment efficacy in juvenile idiopathic arthritis.Ann Rheum Dis
Malattia C, Damasio MB, Pistorio A, Ioseliani M, Vilca I, Valle M, Ruperto N, Viola S, Buoncompagni A, Magnano GM, Ravelli A, Tomà P, Martini A (2011) Development and preliminary validation of a paediatric- targeted MRI scoring system for the assessment of disease activity and damage in juvenile idiopathic arthritis. Ann Rheum Dis 70(3):440–6
Poznanski AK, Hernandez RJ, Guire KE, Bereza UL, Garn SM (1978) Carpal length in children – a useful measurement in the diagnosis of rheumatoid arthritis and some concenital malformation syndromes. Radiology 129(3):661–8
Ravens-Sieberer U, Bullinger M (1998) Assessing the health related quality of life in chronically ill children with the German KINDL: first psychometric and content-analytical results. Qual Life Res 7:399–407
Ruperto N, Pistorio A, Ravelli A, Hasija R, Guseinova D, Filocamo G, Demirkaya E, Malattia C, Martini A; Paediatric Rheumatology International Trials Organisation (PRINTO) (2011) Criteria to define response to therapy in paediatric rheumatic diseases. Eur J Clin Pharmacol 67 Suppl 1:125–31
Varni JW, Burwinkle TM, Szer IS (2004) The PedsQL Multidimensional Fatigue Scale in pediatric rheumatology: reliability and validity. J Rheumatol 31(12):2494–500
Varni JW, Seid M, Smith Knight T, Burwinkle T, Brown J, Szer IS (2002) The PedsQL in pediatric rheumatology: reliability, validity, and responsiveness of the Pediatric Quality of Life Inventory Generic Core Scales and Rheumatology Module. Arthritis Rheum 46(3): 714–25
Viola S, Felici E, Magni-Manzoni S, Pistorio A, Buoncompagni A, Ruperto N, Rossi F, Bartoli M, Martini A, Ravelli A (2005) Development and validation of a clinical index for assessment of long-term damage in juvenile idiopathic arthritis. Arthritis Rheum 52(7):2092–102
Wallace CA, Giannini EH, Huang B, Itert L, Ruperto N; Childhood Arthritis Rheumatology Research Alliance; Pediatric Rheumatology Collaborative Study Group; Paediatric Rheumatology International Trials Organisation (2011) American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis. Arthritis Care Res (Hoboken) 63(7):929–36
Literatur zu Kap. 4.4
Athreya BH, Doughty RA, Bookspan M, Schumacher HR, Sewell EM, Chatten J (1980) Pulmonary manifestations of juvenile rheumatoid arthritis. A report of eight cases and review. Clin Chest Med 1: 361–374
Barnes MG, Grom AA, Thompson SD Griffin TA, Pavlidis P, Itert L, Fall N, Sowders DP, Hinze CH, Aronow BJ, Luyrink LK, Srivastava S, Ilowite NT, Gottlieb BS, Olson JC, Sherry DD, Glass DN, Colbert RA (2009) Subtype-specific peripheral blood gene expression profiles in recent- onset juvenile idiopathic arthritis. Arthritis Rheum. 60:2102–2112
Bechtold S, Ripperger P, Häfner R, Said E, Schwarz HP (2003) Growth hormone improves height in patients with juvenile idiopathic arthritis: 4-year data of a controlled study. J Pediatr 143: 512–519
Beutler B (2004) Inferences, questions and possibilities in Toll-like receptor signalling. Nature 430:257–263
Breit W, Frosch M, Meyer U, Heinecke A, Ganser G (2000) A subgroupspecific evaluation of the efficacy of intraarticular triamcinolone hexacetonide in juvenile chronic arthritis. J Rheumatol 27: 2696–2702
Cassidy JT, Petty RE (eds) (1995) Textbook of pediatric rheumatology, 3rd edn. Saunders, Philadelphia
Cleary AG, Murphy HD, Davidson JE (2003) Intra-articular corticosteroid injections in juvenile idiopathic arthritis. Arch Dis Child 88: 192–196
De Benedetti F, Massa M, Robbioni P, Ravelli A, Burgio GR, Martini A (1991) Correlation of serum interleukin-6 levels with joint involvement and thrombocytosis in systemic juvenile rheumatoid arthritis. Arthritis Rheum 34: 1158–1163
De Benedetti F, Pignatti P, Gerloni V, Massa M, Sartirana P, Caporali R, Montecucco CM, Corti A, Fantini F, Martini A (1997) Differences in synovial fluid cytokine levels between juvenile and adult rheumatoid arthritis. J Rheumatol 24: 1403–1409
De Benedetti F, Brunner HI, Ruperto N Calvo I, Cuttica R, Malattia C, Schneider R, Woo P, Wouters CH, Xavier R, Zemel LS, Wright S, Kenwright A, Martini A, Lovell DJ (2010) Tocilizumab in patients with systemic juvenile idiopathic arthritis: efficacy data from the placebo- controlled 12-week part of the phase 3 TENDER trial. Arthritis Rheum 62:S596
De Jager W, Hoppenreijs EP, Wulffraat NM, Wedderburn LR, Kuis W, Prakken BJ (2007) Blood and synovial fluid cytokine signatures in patients with juvenile idiopathic arthritis: a cross-sectional study. Ann. Rheum. Dis. 66:589–598
De Jager W, Vastert SJ, Beekman JM, Wulffraat NM, Kuis W, Coffer PJ, Prakken BJ (2009) Defective phosphorylation of interleukin-18 receptor [beta] causes impaired natural killer cell function in systemic- onset juvenile idiopathic arthritis. Arthritis Rheum. 60:2782–2793
Dueckers G, Guellac N, Arbogast M, Dannecker G, Foeldvari I, Frosch M, Ganser G, Heiligenhaus A, Horneff G, Illhardt A, Krauspe R, Markus B, Michels H, Schneider M, Singendonk W, Sitter H, Spamer M, Wagner N, Niehues T (2011) Evidence and consensus based treatment guidelines 2010 for juvenile idiopathic arthritis by the german society of paediatric rheumatology. Klin Padiatr 223:386–394
Fall N, Barnes M, Thornton S, Luyrink L, Olson J, Ilowite NT, Gottlieb BS, Griffin T, Sherry DD, Thompson S, Glass DN, Colbert RA, Grom AA (2007) Gene expression profiling of peripheral blood from patients with untreated new-onset systemic juvenile idiopathic arthritis reveals molecular heterogeneity that may predict macrophage activation syndrome. Arthritis Rheum. 56:3793–3804
Frosch M, Vogl T, Seeliger S, Wulffraat N, Kuis W, Viemann D, Foell D, Sorg C, Sunderkotter C, Roth J. (2003) Expression of myeloid-related proteins 8 and 14 in systemic-onset juvenile rheumatoid arthritis. Arthritis Rheum 48: 2622–2626
Frosch M, Metze D, Foell D, Vogl T, Sorg C, Sunderkötter C, Roth J (2005) Early activation of cutaneous vessels and epithelial cells is characteristic of acute systemic onset juvenile idiopathic arthritis. Exp Dermatol 14: 259–265
Frosch M, Roth J (2007) New insights in systemic juvenile idiopathic arthritis – from pathophysiology to treatment. Rheumatology 2008;47:121–125
Frosch M, Ahlmann M, Vogl T, Wittkowski H, Wulffraat N, Foell D, Roth J (2009) The myeloid-related proteins 8 and 14 complex, a novel ligand of toll-like receptor 4, and interleukin-1beta form a positive feedback mechanism in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 60:883–891
Feldmann R, Weglage J, Roth J, Foell D, Frosch M (2005) Systemic juvenile rheumatoid arthritis: cognitive function and social adjustment. Annals of Neurology 58:605–609
Grom AA (2004) Natural killer cell dysfunction. A common pathway in systemic-onset juvenile rheumatoid arthritis, macrophage activtion syndrome, and hemophagocytic lymphohistiocytosis. Arthritis Rheum 50: 689–698
Horneff G, Foeldvari I, Minden K, Moebius D, Hospach T (2011) Report on malignancies in the German juvenile idiopathic arthritis registry. Rheumatol 50:230–236
Holzinger D, Frosch M, Kastrup A, Otten M, Prince F, Suijlekom-Smit L, ten Cate R, Hoppenreijs E, Hansmann S, Moncrieffe H, Ursu S, Wedderburn, L, Roth J, Foell, D and Wittkowski H (2012) The Toll- like receptor 4 agonist MRP8 and MRP14 protein complex is a sensitive indicator for disease activity and predicts relapses in Systemic-Onset Juvenile Idiopathic Arthritis. Ann Rheum Dis 71: 974–980
Hull KM, Shoham N, Chae JJ, Aksentijevich I, Kastner DL (2003) The expanding spectrum of systemic autoinflammatory disorders and their rheumatic manifestations. Current opinion in rheumatology 15:61–69
Kvien TK, Hoyeraal HM, Sandstad B (1986) Azathioprine versus placebo in patients with juvenile rheumatoid arthritis: a single center double blind comparative study. J Rheumatol 13: 118–123
Mouy R, Stephan JL, Pillet P, Haddad E, Hubert P, Prieur AM (1996) Efficacy of cyclosporine A in the treatment of macrophage activation syndrome in juvenile arthritis: Report of five cases. J Pediatr 129: 750–754
Nakajima S, Naruto T, Miyamae T, Imagawa T, Mori M, Nishimaki S, Yokota S (2009) Improvement of reduced serum cartilage oligomeric matrix protein levels in systemic juvenile idiopathic arthritis patients treated with the anti-interleukin-6 receptor monoclonal antibody tocilizumab. Mod. Rheumatol. 19:42–46
Newton RA, Hogg N (1998) The human S100 protein MRP-14 is a novel activator of the beta 2 integrin Mac-1 on neutrophils. J Immunol 160:1427–1435
Nigrovic P, Mannion M, Prince FH, Zeft A, Rabinovich CE, van Rossum MA, Cortis E, Pardeo M, Miettunen PM, Janow G, Birmingham J, Eggebeen A, Janssen E, Shulman AI, Son MB, Hong S, Jones K, Ilowite NT, Cron RQ, Higgins GC (2010) Anakinra as first-line disease modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis Rheum 63:545–55
Okamura H, Tsutsi H, Komatsu T, Yutsudo M, Hakura A, Tanimoto T, Torigoe K, Okura T, Nukada Y, Hattori K, Akita K, Namba M, Tanabe F, Konishi K, Fukuda S, Kurimoto M (1995) Cloning of a new cytokine that induces IFN-gamma production by T cells. Nature 378: 88–91
Pascual V, Allantaz F, Arce E, Punaro M, Banchereaux J (2005) Role of interleukin (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med 201: 1479–1486
Petty RE (1979) Making the diagnosis of Still’s disease. Canad Med Ass J 120: 1480–1481
Petty RE, Southwood TR, Baum J, Bhettay E, Glass DN, Manners P, Maldonado- Cocco J, Suarez-Almazor M, Orozco-Alcala J, Prieur AM (1998) Revision of the proposed classification criteria for juvenile idiopathic arthritis: Durban, 1997. J Rheumatol 25: 1991–1994
Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, He X, Maldonado-Cocco J, Orozco-Alcala J, Prieur AM, Suarez-Almazor ME, Woo P (2004) International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 31: 390–392
Quartier P, Taupin P, Bourdeaut F, Lemelle I, Pillet P, Bost M, Sibilia J, Kone-Paut I, Gandon-Laloum S, LeBideau M, Bader-Meunier B, Mouy R, Debre M, Landais P, Prieur AM (2003) Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. Arthritis Rheum 48: 1093–1101
Quartier P, Allantaz F, Cimaz R, Pillet P, Messiaen C, Bardin C, Bossuyt X, Boutten A, Bienvenu J, Duquesne A, Richer O, Chaussabel D, Mogenet A, Banchereau J, Treluyer JM, Landais P, Pascual V (2011) A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann Rheum Dis 70: 747–754
Ramanan AV, Grom AA (2005) Does systemic-onset juvenile idiopathic arthritis belong under juvenile idiopathic arthritis? Rheumatol 44:1350–1353
Ravelli A (2002) Macrophage activation syndrome. Curr Opin Rheumatol 14: 548–552
Ruperto N, Murray KJ, Gerloni V, Wulffraat N, de Oliveira SK, Falcini F, Dolezalova P, Alessio M, Burgos-Vargas R, Corona F, Vesely R, Foster H, Davidson J, Zulian F, Asplin L, Baildam E, Consuegra JG, Ozdogan H, Saurenmann R, Joos R, Pistorio A, Woo P, Martini A (2004) A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate. Arthritis Rheum 50: 2191–2201
Ruperto N, Quartier P, Wulffraat N, Woo P, Ravelli A, Mouy R, Bader- Meunier B, Vastert SJ, Noseda E, D’Ambrosio D, Lecot J, Chakraborty A, Martini A, Chioato A (2011) A phase II study to evaluate dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features. Arthritis Rheum doi: 10.1002/art.33342
Shimizu M, Yokoyama T, Yamada K, Kaneda H, Wada H, Wada T, Toma T, Ohta K, Kasahara Y, Yachie A (2010) Distinct cytokine profiles of systemic- onset juvenile idiopathic arthritis-associated macrophage activation syndrome with particular emphasis on the role of interleukin- 18 in its pathogenesis. Rheumatology (Oxford) 49:1645–1653
Simon D, Fernando C, Czernichow P, Prieur AM (2002) Linear growth and final height in patients with systemic juvenile idiopathic arthritis treated with longterm glucocorticoids. J Rheumatol 29: 1296–1300
Speckmaier M, Findeisen J, Woo P, Hall A, Sills JA, Price T, Hollingworth P, Craft A, Ansell BM (1989) Low-dose methotrexate in systemic onset juvenile chronic arthritis. Clin Exp Rheumatol 7: 647–650
Stephan JL, Kone-Paut I, Galambrun C, Mouy R, Bader-Meunier B, Prieur AM (2001) Reactive haemophagocytic syndrome in children with inflammatory disorders: A retrospective study of 24 patients. Rheumatology 40: 1285–1292
Still GF (1978) On a form of chronic joint disease in children. Am J Dis Child 132: 195–200, reprinted from Medico-Chirurgical Transactions, vol 80, 1897
Verbsky JW, White AJ (2004) Effective use of the recombinant interleukin 1 receptor antagonist anakinra in therapy resistant systemic onset juvenile rheumatoid arthritis. J Rheumatol 31: 2071–2075
Viemann D, Strey A, Janning A, Jurk K, Klimmek K, Vogl T, Hirono K, Ichida F, Foell D, Kehrel B, Gerke V, Sorg C, Roth J (2005) Myeloidrelated proteins 8 and 14 induce a specific inflammatory response in human microvascular endothelial cells. Blood 105: 2955–2962
Vogl T, Tenbrock K, Ludwig S, Leukert N, Ehrhardt C, van Zoelen MA, Nacken W, Foell D, van der Poll T, Sorg C, Roth J (2007) Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock. Nature medicine 13:1042–1049
Wittkowski H, Frosch M, Wulffraat N, Goldbach-Mansky R, Kallinich T, Kuemmerle-Deschner J, Frühwald MC, Dassmann S, Pham TH, Roth J, Foell D (2008) S100A12 is a novel molecular marker differentiating systemic-onset juvenile idiopathic arthritis from other causes of fever of unknown origin. Arthritis Rheum 58:3924–3931
Woo P (1994) Amyloidosis in children. Baillieres Clin Rheumatol 8: 691–697
Woo P, Wedderburn LR (1998) Juvenile chronic arthritis. Lancet 351: 969–973
Woo P, Southwood TR, Prieur AM, Dore CJ, Grainger J, David J, Ryder C, Hasson N, Hall A, Lemelle I. (2000) Randomized, placebo-controlled, crossover trial of low-dose oral methotrexate in children with extended oligoarticular or systemic arthritis. Arthritis Rheum 43: 1849–1857
Woo P (2006) Systemic juvenile idiopathic arthritis: diagnosis, management, and outcome. Nature Clin Prac Rheumatol 2:28–34
Yokota S, Imagawa T, Mori M, Miyamae T, Aihara Y, Takei S, Iwata N, Umebayashi H, Murata T, Miyoshi M, Tomiita M, Nishimoto N, Kishimoto T (2008) Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, doubleblind, placebo-controlled, withdrawal phase III trial. Lancet 371: 998–1006
Literatur zu Kap. 4.5
Adib N, Silman A, Thomson W (2005) Outcome following onset of juvenile idiopathic inflammatory arthritis: I. frequency of different outcomes. Rheumatology (Oxford) 44:995–1001
Babyn P, Doria AS (2005) Radiologic investigation of rheumatic diseases. Pediatr Clin North Am 52:373–411
Bertamino M, Rossi F, Pistorio A, Lucigrai G, Valle M, Viola S, Magni-Manzoni S, Malattia C, Martini A, Ravelli A (2010) Development and initial validation of a radiographic scoring system for the hip in juvenile idiopathic arthritis. J Rheumatol 37:432–9
Beukelman T, Haynes K, Curtis JR, Xie F, Chen L, Bemrich-Stolz CJ, Delzell E, Saag KG, Solomon DH, Lewis JD; Safety Assessment of Biological Therapeutics Collaboration (2012) Rates of malignancy associated with juvenile idiopathic arthritis and its treatment. Arthritis Rheum 64(4):1263–71
Beukelman T, Patkar NM, Saag KG, Tolleson-Rinehart S, Cron RQ, DeWitt EM, Ilowite NT, Kimura Y, Laxer RM, Lovell DJ, Martini A, Rabinovich CE, Ruperto N (2011) American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res (Hoboken) 63:465–82
Bolt IB, Cannizzaro E, Seger R, Saurenmann RK (2008) Risk factors and longterm outcome of juvenile idiopathic arthritis-associated uveitis in Switzerland. J Rheumatol 35:703–6
Breit W, Frosch M, Meyer U, Heinecke A, Ganser G (2000) A subgroupspecific evaluation of efficacy of triamcinolone hexacetonide in juvenile chronic arthritis. J Rheumatol 27:2696–2702
Breton S, Jousse-Joulin S, Finel E, Marhadour T, Colin D, de Parscau L, Devauchelle-Pensec V (2012) Imaging approaches for evaluating peripheral joint abnormalities in juvenile idiopathic arthritis. Semin Arthritis Rheum 41:698–711
Céspedes-Cruz A, Gutiérrez-Suárez R, Pistorio A, Ravelli A, Loy A, Murray KJ, Gerloni V, Wulffraat N, Oliveira S, Walsh J, Penades IC, Alpigiani MG, Lahdenne P, Saad-Magalhães C, Cortis E, Lepore L, Kimura Y, Wouters C, Martini A, Ruperto N; Pediatric Rheumatology International Trials Organization (PRINTO) (2008) Methotrexate improves the health-related quality of life of children with juvenile idiopathic arthritis. Ann Rheum Dis 67:309–14
Crawley E, Kon S, Woo P (2001) Hereditary predisposition to low interleukin- 10 production in children with extended oligoarticular juvenile idiopathic arthritis. Rheumatology (Oxford) 40:574–8
Díaz-Llopis M, Salom D, Garcia-de-Vicuña C, Cordero-Coma M, Ortega G, Ortego N, Suarez-de-Figueroa M, Rio-Pardo MJ, Fernandez-Cid C, Fonollosa A, Blanco R, Garcia-Aparicio AM, Benitez-Del-Castillo JM, Olea JL, Arevalo JF (2012) Treatment of Refractory Uveitis with Adalimumab: A Prospective Multicenter Study of 131 Patients. Ophthalmology [Epub ahead of print]
Dueckers G, Guellac N, Arbogast M, Dannecker G, Foeldvari I, Frosch M, Ganser G, Heiligenhaus A, Horneff G, Illhardt A, Kopp I, Krauspe R, Markus B, Michels H, Schneider M, Singendonk W, Sitter H, Spamer M, Wagner N, Niehues T (2012) Evidence and consensus based GKJR guidelines for the treatment of juvenile idiopathic arthritis. Clin Immunol 142:176–93
Ellis JA, Munro JE, Ponsonby AL (2010) Possible environmental determinants of juvenile idiopathic arthritis. Rheumatology (Oxford) 49: 411–25
Ferucci ED, Majka DS, Parrish LA, Moroldo MB, Ryan M, Passo M, Thompson SD, Deane KD, Rewers M, Arend WP, Glass DN, Norris JM, Holers VM (2005) Antibodies against cyclic citrullinated peptide are associated with HLA-DR4 in simplex and multiplex polyarticular- onset juvenile rheumatoid arthritis. Arthritis Rheum 52: 239–46
Finnegan S, Clarke S, Gibson D, McAllister C, Rooney M (2011) Synovial membrane immunohistology in early untreated juvenile idiopathic arthritis: differences between clinical subgroups. Ann Rheum Dis 70:1842–50
Flato B, Lien G, Smerdel A, Vinje O, Dale K, Johnston V, Sorskaar D, Moum T, Ploski R, Forre O. Prognostic factors in juvenile rheumatoid arthritis: a case-control study revealing early predictors and outcome after 14.9 years. J Rheumatol 2003;30:386–93
Foeldvari I, Szer IS, Zemel LS, Lovell DJ, Giannini EH, Robbins JL, West CR, Steidle G, Krishnaswami S, Bloom BJ (2009) A prospective study comparing celecoxib with naproxen in children with juvenile rheumatoid arthritis. J Rheumatol 36:174–82
Frosch M, Foell D, Ganser G, Roth J (2003) Arthrosonography of hip and knee joints int the follow up of juvenile rheumatoid arthritis. Ann Rheum Dis 62: 242–244
Ganser G, Winowski H (2006) Sonographie in der Kinder- und Jugendrheumatologie. Akt Rheumatol 31:139–147
Ganser G (2011) Schmerzen und Schwellungen der Gelenke und Knochen. In: Michalk, D, Schönau E (Hrsg.) Differenzialdiagnose Pädiatrie, 3. Aufl., S. 612–630. Urban & Schwarzenberg, München
Giannini EH, Brewer EJ, Miller ML, Gibbas D, Passo MH, Hoyeraal HM, Bernstein B, Person DA, Fink CW, Sawyer LA, et al. (1990) Ibuprofen suspension in the treatment of juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. J Pediatr 117: 645–52
Graham TB, Laor T, Dardzinski BJ (2005) Quantitative magnetic resonance imaging of the hands and wrists of children with juvenile rheumatoid arthritis. J Rheumatol 32:1811–20
Guillaume S, Prieur AM, Coste J, Job-Deslandre C (2000) Long-term outcome and prognosis in oligoarticular-onset juvenile idiopathic arthritis. Arthritis Rheum 43:1858–65
Heiligenhaus A, Michels H, Schumacher C, Kopp I, Neudorf U, Niehues T, Baus H, Becker M, Bertram B, Dannecker G, Deuter C, Foeldvari I, Frosch M, Ganser G, Gaubitz M, Gerdes G, Horneff G, Illhardt A, Mackensen F, Minden K, Pleyer U, Schneider M, Wagner N, Zierhut M (2012) Evidence-based, interdisciplinary guidelines for anti-inflammatory treatment of uveitis associated with juvenile idiopathic arthritis. Rheumatol Int 32:1121–33
Heiligenhaus A, Niewerth M, Ganser G, Heinz C, Minden K; German Uveitis in Childhood Study Group (2007) Prevalence and complications of uveitis in juvenile idiopathic arthritis in a populationbased nation-wide study in Germany: suggested modification of the current screening guidelines. Rheumatology (Oxford) 46: 1015–9
Horneff G, De Bock F, Foeldvari I, Girschick HJ, Michels H, Moebius D, Schmeling H; German and Austrian Paediatric Rheumatology Collaborative Study Group (2009) Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry.Ann Rheum Dis 68:519–25
Horneff G, Foeldvari I, Minden K, Moebius D, Hospach T (2011) Report on malignancies in the German juvenile idiopathic arthritis registry. Rheumatology (Oxford) 50:230–6
Hyrich KL, Lal SD, Foster HE, Thornton J, Adib N, Baildam E, Gardner- Medwin J, Wedderburn LR, Chieng A, Davidson J, Thomson W (2010) Disease activity and disability in children with juvenile idiopathic arthritis one year following presentation to paediatric rheumatology. Results from the Childhood Arthritis Prospective Study. Rheumatology (Oxford) 49:116–22
Jones OY, Spencer CH, Bowyer SL, Dent PB, Gottlieb BS, Rabinovich CE (2006) A multicenter case-control study on predictive factors distinguishing childhood leukemia from juvenile rheumatoid arthritis. Pediatrics 117:e840–4
Kamphuis S, Kuis W, de Jager W, Teklenburg G, Massa M, Gordon G, Boerhof M, Rijkers GT, Uiterwaal CS, Otten HG, Sette A, Albani S, Prakken BJ (2005) Tolerogenic immune responses to novel T-cell epitopes from heat-shock protein 60 in juvenile idiopathic arthritis. Lancet 366:50–6
Kotaniemi K, Arkela-Kautiainen M, Haapasaari J, Leirisalo-Repo M (2005) Uveitis in young adults with juvenile idiopathic arthritis: a clinical evaluation of 123 patients. Ann Rheum Dis 64:871–4
Kotaniemi K, Savolainen A, Karma A, Aho K (2003) Recent advances in uveitis of juvenile idiopathic arthritis. Surv Ophthalmol 48:489–502
Kvien TK, Høyeraal HM, Sandstad B (1984) Naproxen and acetylsalicylic acid in the treatment of pauciarticular and polyarticular juvenile rheumatoid arthritis. Assessment of tolerance and efficacy in a single-centre 24-week double-blind parallel study. Scand J Rheumatol 13:342–50
Lamer S, Sebag GH (2000) MRI and ultrasound in children with juvenile chronic arthritis. Eur J Radiol 33:85–93
Laxer RM, Clarke HM (2000) Rheumatic disorders of the hand and wrist in childhood and adolescence. Hand Clin 16:659–71
Leak AM, Richter MR, Clemens LE, Hall MA, Ansell BM (1988) A crossover study of naproxen, diclofenac and tolmetin in seronegative juvenile chronic arthritis. Clin Exp Rheumatol 6(2):157–60
Lin YT, Wang CT, Gershwin ME, Chiang BL (2011) The pathogenesis of oligoarticular/polyarticular vs systemic juvenile idiopathic arthritis. Autoimmun Rev 10:482–9
Lovell DJ, Giannini EH, Reiff A, Cawkwell GD, Silverman ED, Nocton JJ, Stein LD, Gedalia A, Ilowite NT, Wallace CA, Whitmore J, Finck BK (2000) Etanercept in children with polyarticular juvenile rheumatoid rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med 342:763–9
Lovell DJ, Ruperto N, Goodman S, Reiff A, Jung L, Jarosova K, Nemcova D, Mouy R, Sandborg C, Bohnsack J, Elewaut D, Foeldvari I, Gerloni V, Rovensky J, Minden K, Vehe RK, Weiner LW, Horneff G, Huppertz HI, Olson NY, Medich JR, Carcereri-De-Prati R, McIlraith MJ, Giannini EH, Martini A; Pediatric Rheumatology Collaborative Study Group; Pediatric Rheumatology International Trials Organisation (2008) Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med 359:810–20
Macaubas C, Nguyen K, Milojevic D, Park JL, Mellins ED (2009) Oligoarticular and polyarticular JIA: epidemiology and pathogenesis. Nat Rev Rheumatol 5:616–26
Magni-Manzoni S, Epis O, Ravelli A, Klersy C, Veisconti C, Lanni S, Muratore V, Sciré CA, Rossi S, Montecucco C (2009) Comparison of clinical versus ultrasound-determined synovitis in juvenile idiopathic arthritis. Arthritis Rheum 61:1497–504
Malattia C, Damasio MB, Magnaguagno F, Pistorio A, Valle M, Martinoli C, Viola S, Buoncompagni A, Loy A, Ravelli A, Tomà P, Martini A (2008) Magnetic resonance imaging, ultrasonography, and conventional radiography in the assessment of bone erosions in juvenile idiopathic arthritis. Arthritis Rheum 59:1764–72
Malattia C, Damasio MB, Pistorio A, Ioseliani M, Vilca I, Valle M, Ruperto N, Viola S, Buoncompagni A, Magnano GM, Ravelli A, Tomà P, Martini A (2011) Development and preliminary validation of a paediatric- targeted MRI scoring system for the assessment of disease activity and damage in juvenile idiopathic arthritis. Ann Rheum Dis 70:440–6
Marmor MF, Kellner U, Lai TY, Lyons JS, Mieler WF; American Academy of Ophthalmology (2011) Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Ophthalmology 118:415–22
McGhee JL, Burks FN, Sheckels JL, Jarvis JN (2002) Identifying children with chronic arthritis based on chief complaints: absence of predictive value for musculoskeletal pain as an indicator of rheumatic disease in children. Pediatrics 110:354–9
Merino R, de Inocencio J, Garcia-Consuegra J () Evaluation of revised International League of Associations for Rheumatology classification criteria for juvenile idiopathic arthritis in Spanish children (Edmonton 2001). J Rheumatol 2005 32:559–61
Minden K, Niewerth M, Listing J, Biedermann T, Bollow M, Schontube M, Zink A () Long-term outcome in patients with juvenile idiopathic arthritis. Arthritis Rheum 2002 46:2392–401
Minden K, Niewerth M () Kerndokumentation und Prognose. Monatsschrift Kinderheilk 2012 160:237–43
Murray KJ, Grom AA, Thompson SD, Lieuwen D, Passo MH, Glass DN (1998) Contrasting cytokine profiles in the synovium of different forms of juvenile rheumatoid arthritis and juvenile spondyloarthropathy: prominence of interleukin 4 in restricted disease. J Rheumatol 25:1388–98
Niehues T, Horneff G, Michels H, Hock MS, Schuchmann L (2005) Evidence- based use of methotrexate in children with rheumatic diseases: a consensus statement of the Working Groups Pediatric Rheumatology Germany (AGKJR) and Pediatric Rheumatology Austria. Rheumatol Int 25:169–78
Nistala K, Moncrieffe H, Newton KR, Varsani H, Hunter P, Wedderburn LR (2008) Interleukin-17-producing T cells are enriched in the joints of children with arthritis, but have a reciprocal relationship to regulatory T cell numbers. Arthritis Rheum 58:875–87
Oen K, Duffy CM, Tse SM, Ramsey S, Ellsworth J, Chédeville G, Chetaille AL, Saint-Cyr C, Cabral DA, Spiegel LR, Schneider R, Lang B, Huber AM, Dancey P, Silverman E, Rosenberg AM, Cameron B, Johnson N, Dorval J, Scuccimarri R, Campillo S, Petty RE, Duffy KN, Boire G, Haddad E, Houghton K, Laxer R, Turvey SE, Miettunen P, Gross K, Guzman J, Benseler S, Feldman BM, Espinosa V, Yeung RS, Tucker L (2010) Early outcomes and improvement of patients with juvenile idiopathic arthritis enrolled in a Canadian multicenter inception cohort. Arthritis Care Res (Hoboken) 62:527–36
Oen K, Reed M, Malleson PN, Cabral DA, Petty RE, Rosenberg AM, Cheang M (2003) Radiologic outcome and its relationship to functional disability in juvenile rheumatoid arthritis. J Rheumatol 30: 832–40
Padeh S, Passwell JH (1998) Intraarticular corticosteroid injection in the management of children with chronic arthritis. Arthritis Rheum 41:1210–4
Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, He X, Maldonado-Cocco J, Orozco-Alcala J, Prieur AM, Suarez-Almazor ME, Woo P; International League of Associations for Rheumatology (2004) International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 31:390–2
Prahalad S, Glass DN (2002) Is juvenile rheumatoid arthritis/juvenile idiopathic arthritis different from rheumatoid arthritis? Arthritis Res 4(suppl 3):303–10
Quartier P, Taupin P, Bourdeaut F, Lemelle I, Pillet P, Bost M, Sibilia J, Kone-Paut I, Gandon-Laloum S, LeBideau M, Bader-Meunier B, Mouy R, Debre M, Landais P, Prieur AM (2003) Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. Arthritis Rheum 48:1093–101
Ravelli A, Ioseliani M, Norambuena X, Sato J, Pistorio A, Rossi F, Ruperto N, Magni-Manzoni S, Ullmann N, Martini A (2007) Adapted versions of the Sharp/van der Heijde score are reliable and valid for assessment of radiographic progression in juvenile idiopathic arthritis. Arthritis Rheum 56:3087–95
Ravelli A, Varnier GC, Oliveira S, Castell E, Arguedas O, Magnani A, Pistorio A, Ruperto N, Magni-Manzoni S, Galasso R, Lattanzi B, Dalprà S, Battagliese A, Verazza S, Allegra M, Martini A (2011) Antinuclear antibody-positive patients should be grouped as a separate category in the classification of juvenile idiopathic arthritis. Arthritis Rheum 63:267–75
Rossi F, Di Dia F, Galipò O, Pistorio A, Valle M, Magni-Manzoni S, Ruperto N, Tomà P, Martini A, Ravelli A (2006) Use of the Sharp and Larsen scoring methods in the assessment of radiographic progression in juvenile idiopathic arthritis. Arthritis Rheum 55:717–23
Ruperto N, Lovell DJ, Cuttica R, Wilkinson N, Woo P, Espada G, Wouters C, Silverman ED, Balogh Z, Henrickson M, Apaz MT, Baildam E, Fasth A, Gerloni V, Lahdenne P, Prieur AM, Ravelli A, Saurenmann RK, Gamir ML, Wulffraat N, Marodi L, Petty RE, Joos R, Zulian F, McCurdy D, Myones BL, Nagy K, Reuman P, Szer I, Travers S, Beutler A, Keenan G, Clark J, Visvanathan S, Fasanmade A, Raychaudhuri A, Mendelsohn A, Martini A, Giannini EH; Paediatric Rheumatology International Trials Organisation; Pediatric Rheumatology Collaborative Study Group (2007) A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticularcourse juvenile rheumatoid arthritis. Arthritis Rheum 56:3096–106
Ruperto N, Lovell DJ, Quartier P, Paz E, Rubio-Pérez N, Silva CA, Abud- Mendoza C, Burgos-Vargas R, Gerloni V, Melo-Gomes JA, Saad- Magalhães C, Sztajnbok F, Goldenstein-Schainberg C, Scheinberg M, Penades IC, Fischbach M, Orozco J, Hashkes PJ, Hom C, Jung L, Lepore L, Oliveira S, Wallace CA, Sigal LH, Block AJ, Covucci A, Martini A, Giannini EH; Paediatric Rheumatology International Trials Organization; Pediatric Rheumatology Collaborative Study Group (2008) Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet 372:383–91
Ruperto N, Murray KJ, Gerloni V, Wulffraat N, de Oliveira SK, Falcini F, Dolezalova P, Alessio M, Burgos-Vargas R, Corona F, Vesely R, Foster H, Davidson J, Zulian F, Asplin L, Baildam E, Consuegra JG, Ozdogan H, Saurenmann R, Joos R, Pistorio A, Woo P, Martini A; Pediatric Rheumatology International Trials Organization (2004) A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate. Arthritis Rheum 50:2191–201
Ruperto N, Nikishina I, Pachanov ED, Shachbazian Y, Prieur AM, Mouy R, Joos R, Zulian F, Schwarz R, Artamonova V, Emminger W, Bandeira M, Buoncompagni A, Foeldvari I, Falcini F, Baildam E, Kone-Paut I, Alessio M, Gerloni V, Lenhardt A, Martini A, Hanft G, Sigmund R, Simianer S; Pediatric Rheumatology International Trials Organization (2005) A randomized, double-blind clinical trial of two doses of meloxicam compared with naproxen in children with juvenile idiopathic arthritis: short- and long-term efficacy and safety results. Arthritis Rheum 52:563–72
Saurenmann RK, Levin AV, Feldman BM, Rose JB, Laxer RM, Schneider R, Silverman ED (2007) Prevalence, risk factors, and outcome of uveitis in juvenile idiopathic arthritis: a long-term followup study. Arthritis Rheum 56:647–57
Sherry DD, Stein LD, Reed AM, Schanberg LE, Kredich DW http://www. ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=10555028&query_hl=28 (1999) Prevention of leg length discrepancy in young children with pauciarticular juvenile rheumatoid arthritis by treatment with intraarticular steroids. Arthritis Rheum 42:2330–4
Silverman E, Mouy R, Spiegel L, Jung LK, Saurenmann RK, Lahdenne P, Horneff G, Calvo I, Szer IS, Simpson K, Stewart JA, Strand V; Leflunomide in Juvenile Rheumatoid Arthritis (JRA) Investigator Group (2005) Leflunomide or methotrexate for juvenile rheumatoid arthritis. N Engl J Med 352:1655–66
Skarin A, Elborgh R, Edlund E, et al. (2009) Long-term follow-up of patients with uveitis associated with juvenile idiopathic arthritis: a cohort study. Ocul Immunol Inflamm 17:104–8
Smith JA, Thompson DJ, Whitcup SM, Suhler E, Clarke G, Smith S, Robinson M, Kim J, Barron KS (2005) A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis. Arthritis Rheum 53:18–23
Spamer M, Häfner R, Truckenbrodt H (2001) Physiotherapie in der Kinderrheumatologie. Pflaum, München Spamer M, Georgi M, Häfner R, Händel H, König M, Haas JP (2012) Physiotherapie für die juvenile idiopathische Arthritis. Z Rheumatol 71:387–95
Thomas E, Symmons DP, Brewster DH, Black RJ, Macfarlane GJ (2003) National study of cause-specific mortality in rheumatoid arthritis, juvenile chronic arthritis, and other rheumatic conditions: a 20 year followup study. J Rheumatol 30:958–65
Tsitsami E, Bozzola E, Magni-Manzoni S, Viola S, Pistorio A, Ruperto N, Martini A, Ravelli A (2003) Positive family history of psoriasis does not affect the clinical expression and course of juvenile idiopathic arthritis patients with oligoarthritis. Arthritis Rheum 49:488–93
Twilt M, Mobers SM, Arends LR, ten Cate R, van Suijlekom-Smit L (2004) Temporomandibular involvement in juvenile idiopathic arthritis. J Rheumatol 31:1418–22
van Dijken TD, Vastert SJ, Gerloni VM, Pontikaki I, Linnemann K, Girschick H, Armbrust W, Minden K, Prince FH, Kokke FT, Nieuwenhuis EE, Horneff G, Wulffraat NM (2011) Development of inflammatory bowel disease in patients with juvenile idiopathic arthritis treated with etanercept. J Rheumatol 38:1441–6
van Rossum MA, Fiselier TJ, Franssen MJ, Zwinderman AH, ten Cate R, van Suijlekom-Smit LW, van Luijk WH, van Soesbergen RM, Wulffraat NM, Oostveen JC, Kuis W, Dijkstra PF, van Ede CF, Dijkmans BA (1998) Sulfasalazine in the treatment of juvenile chronic arthritis: a randomized, double-blind, placebo-controlled, multicenter study. Dutch Juvenile Chronic Arthritis Study Group. Arthritis Rheum 41:808–16
van Rossum MA, Zwinderman AH, Boers M, Dijkmans BA, van Soesbergen RM, Fiselier TJ, Franssen MJ, ten Cate R, van Suijlekom-Smit LW, Wulffraat NM, Kuis W, van Luijk WH, Oostveen JC, Dijkstra PF; Dutch Juvenile Idiopathic Arthritis Study Group (2003) Radiologic features in juvenile idiopathic arthritis: a first step in the development of a standardized assessment method. Arthritis Rheum 48:507–15
Vercoulen Y, van Teijlingen NH, de Kleer IM, Kamphuis S, Albani S, Prakken BJ (2009) Heat shock protein 60 reactive T cells in juvenile idiopathic arthritis: what is new? Arthritis Res Ther 11:231
Wedderburn LR (2004) T cell regulation in juvenile arthritis. Pediatric Rheumatology Online Journal 2:306–22
Wehrens EJ, Mijnheer G, Duurland CL, Klein M, Meerding J, van Loosdregt J, de Jager W, Sawitzki B, Coffer PJ, Vastert B, Prakken BJ, van Wijk F (2011) Functional human regulatory T cells fail to control autoimmune inflammation due to PKB/c-akt hyperactivation in effector cells. Blood 118:3538–48
Woo P, Southwood TR, Prieur AM, Doré CJ, Grainger J, David J, Ryder C, Hasson N, Hall A, Lemelle I 2000 () Randomized, placebo-controlled, crossover trial of low-dose oral methotrexate in children with extended oligoarticular or systemic arthritis. Arthritis Rheum 43:1849–57
Wouters CH, Ceuppens JL, Stevens EA (2002) Different circulating lymphocyte profiles in patients with different subtypes of juvenile idiopathic arthritis. Clin Exp Rheumatol 20:239–48
Zak M, Fledelius H, Pedersen FK (2003) Ocular complications and visual outcome in juvenile chronic arthritis: a 25-year follow-up study. Acta Ophthalmol Scand 81:211–5
Zulian F, Martini G, Gobber D, Agosto C, Gigante C, Zacchello F (2003) Comparison of intra-articular triamcinolone hexacetonide and triamcinolone acetonide in oligoarticular juvenile idiopathic arthritis. Rheumatology (Oxford) 42:1254–9
Zulian F, Martini G, Gobber D, Plebani M, Zacchello F, Manners P (2004) Triamcinolone acetonide and hexacetonide intraarticular treatment of symmetrical joints in juvenile idiopathic arthritis: a double-blind trial. Rheumatology (Oxford) 43:1288–1291
Literatur zu Kap. 4.6
Angeles-Han S, Prahalad S (2010) The genetics of juvenile idiopathic arthritis: what is new in 2010? Current rheumatology reports 12: 87–93
Akikusa JD, Weinstein M, Laxer RM (2005) Clinical images: Pachydermodactyly. Arthritis Rheum 52: 990
Alsufyani K, Ortiz-Alvarez O, Cabral DA, Tucker LB, Petty RE, Malleson PN (2004) The role of subcutaneous administration of methotrexate in children with juvenile idiopathic arthritis who have failed oral methotrexate. J Rheumatol 31: 179–182
Barnes MG, Grom AA, Thompson SD, Griffin TA, Luyrink LK, Colbert RA, Glass DN (2010) Biologic similarities based on age at onset in oligoarticular and polyarticular subtypes of juvenile idiopathic arthritis. Arthritis Rheum 62: 3249–58
Beukelman T, Patkar NM, Saag KG, Tolleson-Rinehart S, Cron RQ, DeWitt EM, Ilowite NT, Kimura Y, Laxer RM, Lovell DJ, Martini A, Rabinovich CE, Ruperto N (2011) 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res (Hoboken) 63: 465–82
Bowyer SL, Roettcher PA, Higgins GC, Adams B, Myers LK, Wallace C, Rennebohm R, Moore TL, Pepmueller PH, Spencer C, Wagner- Weiner L, Rabinovich E, Passo M, Lovell DJ, McCurdy D, Zemel L, Schikler KN, Szer I, Kurtin P, Lindsley C (2003) Health status of patients with juvenile rheumatoid arthritis at 1 and 5 years after diagnosis. J Rheumatol 30: 394–400
Breit W, Frosch M, Meyer U, Heinecke A, Ganser G (2000) A subgroupspecific evaluation of the efficacy of intraarticular triamcinolone hexacetonide in juvenile chronic arthritis. J Rheumatol 27: 2696–2702
Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, Lines C, Riddell R, Morton D, Lanas A, Konstam MA, Baron JA, the Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators (2005) Cardiovascular events associated with Rofecoxib in a Colorectal Adenoma Chemoprevention Trial. N Engl J Med 352: 1092–1102
Brooks CD (2001) Sulfasalazine for the management of juvenile rheumatoid arthritis. J Rheumatol 28: 845–853
Brunner J, Sitzmann FC (2006) The diagnostic value of anti-cyclic citrullinated peptide (CCP) antibodies in children with Juvenile Idiopathic Arthritis. Clin Exp Rheumatol 24: 449–451
Cespedes-Cruz A, Gutierrez-Suarez R, Pistorio A, Ravelli A, Loy A, Murray KJ, Gerloni V, Wulffraat N, Oliveira S, Walsh J, Penades IC, Alpigiani MG, Lahdenne P, Saad-Magalhaes C, Cortis E, Lepore L, Kimura Y, Wouters C, Martini A, Ruperto N (2008) Methotrexate improves the health-related quality of life of children with juvenile idiopathic arthritis. Ann Rheum Dis 67: 309–314
Choy EH, Panayi GS (2001) Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 344: 907–916
Cleary AG, Murphy HD, Davidson JE (2003) Intra-articular corticosteroid injections in juvenile idiopathic arthritis. Arch Dis Child 88: 192–196
Collado P, Jousse-Joulin S, Alcalde M, Naredo E, D’Agostino MA (2012) Is ultrasound a validated imaging tool for the diagnosis and management of synovitis in juvenile idiopathic arthritis? A systematic literature review. Arthritis care & research 64: 1011–1019
Diak P, Siegel J, La Grenade L, Choi L, Lemery S, McMahon A (2010) Tumor necrosis factor alpha blockers and malignancy in children: forty-eight cases reported to the Food and Drug Administration. Arthritis Rheum 62: 2517–2524
Dueckers G, Guellac N, Arbogast M, Dannecker G, Foeldvari I, Frosch M, Ganser G, Heiligenhaus A, Horneff G, Illhardt A, Krauspe R, Markus B, Michels H, Schneider M, Singendonk W, Sitter H, Spamer M, Wagner N, Niehues T; German Society of Paediatric Rheumatology (2011) Interdisziplinäre S2-Therapieleitlinie der Juvenilen Idiopathischen Arthritis (2. Auflage). Klin Padiatr 223: 386–94
Dueckers G, Guellac N, Arbogast M, Dannecker G, Foeldvari I, Frosch M, Ganser G, Heiligenhaus A, Horneff G, Illhardt A, Kopp I, Krauspe R, Markus B, Michels H, Schneider M, Singendonk W, Sitter H, Spamer M, Wagner N, Niehues T (2012) Evidence and consensus based GKJR guidelines for the treatment of juvenile idiopathic arthritis. Clin Immunol 142: 176–193
Edwards JCW, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, Stevens RM, Shaw T (2004) Efficacy of B-Cell-Targeted Therapy with Rituximab in Patients with Rheumatoid Arthritis. N Engl J Med 350: 2572–2581
Elhai M, Wipff J, Bazeli R, Freire V, Feydy A, Drape J, Quartier P, Kahan A, Job-Deslandre C (2012) Radiological cervical spine involvement in young adults with polyarticular juvenile idiopathic arthritis. Rheumatology (Oxford, England)
Flato B, Lien G, Smerdel A, Vinje O, Dale K, Johnston V, Sorskaar D, Moum T, Ploski R, Forre O (2003) Prognostic factors in juvenile rheumatoid arthritis: a case-control study revealing early predictors and outcome after 14.9 years. J Rheumatol 30: 386–393
Foeldvari I, Szer IS, Zemel LS, Lovell DJ, Giannini EH, Robbins JL, West CR, Steidle G, Krishnaswami S, Bloom BJ (2009) A prospective study comparing celecoxib with naproxen in children with juvenile rheumatoid arthritis. J Rheumatol 36: 174–182
Foell D, Wulffraat N, Wedderburn LR, Wittkowski H, Frosch M, Gerss J, Stanevicha V, Mihaylova D, Ferriani V, Tsakalidou FK, Foeldvari I, Cuttica R, Gonzalez B, Ravelli A, Khubchandani R, Oliveira S, Armbrust W, Garay S, Vojinovic J, Norambuena X, Gamir ML, García- Consuegra J, Lepore L, Susic G, Corona F, Dolezalova P, Pistorio A, Martini A, Ruperto N, Roth J; Paediatric Rheumatology International Trials Organization (PRINTO) (2010) Methotrexate withdrawal at 6 vs 12 months in juvenile idiopathic arthritis in remission: a randomized clinical trial. JAMA 303: 1266–73
Forre O, Sioud M (1993) T cell receptor variable region gene usage in juvenile chronic arthritis. Clin Exp Rheumatol 11 (Suppl 9): S43–S46
Foster HE, Marshall N, Myers A, Dunkley P, Griffiths ID (2003) Outcome in adults with juvenile idiopathic arthritis: a quality of life study. Arthritis Rheum 48: 767–775
Frosch M, Strey A, Vogl T, Wulffraat NM, Kuis W, Sunderkotter C, Harms E, Sorg C, Roth J (2000) Myeloid-related proteins 8 and 14 are specifically secreted during interaction of phagocytes and activated endothelium and are useful markers for monitoring disease activity in pauciarticular-onset juvenile rheumatoid arthritis. Arthritis Rheum 43: 628–637
Frosch M, Foell D, Ganser G, Roth J (2003) Arthrosonography of hip and knee joints in the follow up of juvenile rheumatoid arthritis. Ann Rheum Dis 62: 242–244
Gare BA, Fasth A (1995) The natural history of juvenile chronic arthritis: a population based cohort study. I. Onset and disease process. J Rheumatol 22: 295–307
Gerloni V, Cimaz R, Gattinara M, Arnoldi C, Pontikaki I, Fantini F (2001) Efficacy and safety profile of cyclosporin A in the treatment of juvenile chronic (idiopathic) arthritis. Results of a 10-year prospective study. Rheumatology (Oxford) 40: 907–913
Gerloni V, Pontikaki I, Gattinara M, Desiati F, Lupi E, Lurati A, Salmaso A, Fantini F (2005) Efficacy of repeated intravenous infusions of an anti-tumor necrosis factor alpha monoclonal antibody, infliximab, in persistently active, refractory juvenile idiopathic arthritis: results of an open-label prospective study. Arthritis Rheum 52: 548–553
Gerss J, Roth J, Holzinger D, Ruperto N, Wittkowski H, Frosch M, Wulffraat N, Wedderburn L, Stanevicha V, Mihaylova D, Harjacek M, Len C, Toppino C, Masi M, Minden K, Saurenmann T, Uziel Y, Vesely R, Apaz MT, Kuester RM, Rua Elorduy MJ, Burgos-Vargas R, Ioseliani M, Magni-Manzoni S, Unsal E, Anton J, Balogh Z, Hagelberg S, Mazur- Zielinska H, Tauber T, Martini A, Foell D (2012) Phagocyte-specific S100 proteins and high-sensitivity C-reactive protein as biomarkers for a risk-adapted therapy to maintain remission in juvenile idiopathic arthritis: a comparative study. Ann Rheum Dis 11 June 2012 (Epub ahead of print)
Giannini EH, Brewer EJ, Kuzmina N, Shaikov A, Maximov A, Vorontsov I, Fink CW, Newman AJ, Cassidy JT, Zemel LS (1992) Methotrexate in resistant juvenile rheumatoid arthritis. Results of the U.S.A.–U.S.S.R. double-blind, placebo-controlled trial. The Pediatric Rheumatology Rheumatology Collaborative Study Group and The Cooperative Children‘s Study Group. N Engl J Med 326: 1043–1049
Giannini EH, Ilowite NT, Lovell DJ, Wallace CA, Rabinovich CE, Reiff A, Higgins G, Gottlieb B, Singer NG, Chon Y, Lin SL, Baumgartner SW (2009) Long-term safety and effectiveness of etanercept in children with selected categories of juvenile idiopathic arthritis. Arthritis Rheum 60: 2794–2804
Gottlieb BS, Keenan GF, Lu T, Ilowite NT (1997) Discontinuation of methotrexate treatment in juvenile rheumatoid arthritis. Pediatrics 100: 994–997
Haapasaari J, Kautiainen HJ, Isomaki HA, Hakala M (2004) Etanercept does not essentially increase the total costs of the treatment of refractory juvenile idiopathic arthritis. J Rheumatol 31: 2286–2289
Habib GS (2009) Systemic effects of intra-articular corticosteroids. Clin Rheumatol 28: 749–756
Haufe S, Haug M, Schepp C, Kuemmerle-Deschner J, Hansmann S, Rieber N, Tzaribachev N, Hospach T, Maier J, Dannecker GE, Holzer U (2011) Impaired suppression of synovial fluid CD4+CD25- T cells from patients with juvenile idiopathic arthritis by CD4+CD25+ Treg cells. Arthritis Rheum 63: 3153–3162
Hofer M, Southwood TR (2002) Classification of childhood arthritis. Best Pract Res Clin Rheumatol 16: 379–396
Hollenbach JA, Thompson SD, Bugawan TL, Ryan M, Sudman M, Marion M, Langefeld CD, Thomson G, Erlich HA, Glass DN (2010) Juvenile idiopathic arthritis and HLA class I and class II interactions and age-at-onset effects. Arthritis Rheum 62: 1781–91
Horneff G, Schmeling H, Biedermann T, Foeldvari I, Ganser G, Girschick HJ, Hospach T, Huppertz HI, Keitzer R, Kuster RM, Michels H, Moebius D, Rogalski B, Thon A (2004) The German etanercept registry for treatment of juvenile idiopathic arthritis. Ann Rheum Dis 63: 1638–1644
Horneff G, Hospach T, Dannecker G, Föll D, Haas JP, Girschick HJ, Huppertz HI, Keitzer R, Laws HJ, Michels H, Minden K, Trauzeddel R (2010) Updated statement by the German Society for Pediatric and Adolescent Rheumatology (GKJR) on the FDA›s report regarding malignancies in anti-TNF-treated patients from Aug. 4, 2009. Z Rheumatol 69: 561–567
Horneff G, De Bock F, Foeldvari I, Girschick HJ, Michels H, Moebius D, Schmeling H (2009) Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry. Ann Rheum Dis 68: 519–525
Hull RG (2001) Guidelines for the management of childhood arthritis. Rheumatology (Oxford) 40: 1309–1312
Jarvis JN (1998) Pathogenesis and mechanisms of inflammation in the childhood rheumatic diseases. Curr Opin Rheumatol 10: 459–467
Johnson K, Gardner-Medwin J (2002) Childhood arthritis: classification and radiology. Clin Radiol 57: 47–58
Keystone EC (2005) Safety of biologic therapies – an update. J Rheumatol (Suppl 74): 8–12
Kremer JM, Westhovens R, Leon M, Di Giorgio E, Alten R, Steinfeld S, Russell A, Dougados M, Emery P, Nuamah IF, Williams GR, Becker JC, Hagerty DT, Moreland LW (2003) Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 349: 1907–1915
Kuseler A, Pedersen TK, Gelineck J, Herlin T (2005) A 2 year followup study of enhanced magnetic resonance imaging and clinical examination of the temporomandibular joint in children with juvenile idiopathic arthritis. J Rheumatol 32: 162–169
Kvien TK, Hoyeraal HM, Sandstad B (1986) Azathioprine versus placebo in patients with juvenile rheumatoid arthritis: a single center double blind comparative study. J Rheumatol 13: 118–123
Lahdenne P, Vahasalo P, Honkanen V (2003) Infliximab or etanercept in the treatment of children with refractory juvenile idiopathic arthritis: an open label study. Ann Rheum Dis 62: 245–247
Lovell D (2004) Biologic agents for the treatment of juvenile rheumatoid arthritis: current status. Paediatr Drugs 6: 137–146
Lovell DJ, Giannini EH, Reiff A, Cawkwell GD, Silverman ED, Nocton JJ, Stein LD, Gedalia A, Ilowite NT, Wallace CA, Whitmore J, Finck BK (2000) Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med 342: 763–769
Lovell DJ, Giannini EH, Reiff A, Jones OY, Schneider R, Olson JC, Stein LD, Gedalia A, Ilowite NT, Wallace CA, Lange M, Finck BK, Burge DJ (2003) Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: interim results from an ongoing multicenter, open-label, extended-treatment trial. Arthritis Rheum 48: 218–226
Lovell D, Ruperto N, Goodman S, Reiff A, Martini A, Giannini EH, Radin AR, Rao VS, Spencer-Green G (2004) Preliminary data from the study of adalimumab in children with juvenile idiopathic arthritis. Arthritis Rheum 50 (Suppl): S436
Lovell J, Ruperto N, Goodman S, Reiff A, Jung L, Jarosova K, Nemcova D, Mouy R, Sandborg C, Bohnsack J, Elewaut D, Foeldvari I, Gerloni V, Rovensky J, Minden K, Vehe RK, Weiner LW, Horneff G, Huppertz HI, Olson NY, Medich JR, Carcereri-De-Prati R, McIlraith MJ, Giannini EH, Martini A (2008) Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med 359: 810–820
Mangge H, Schauenstein K (1998) Cytokines in juvenile rheumatoid arthritis (JRA). Cytokine 10: 471–480
Martini A (2003) Are the number of joints involved or the presence of psoriasis still useful tools to identify homogeneous disease entities in juvenile idiopathic arthritis? J Rheumatol 30: 1900–1903
Martini A (2012) It is time to rethink juvenile idiopathic arthritis classification and nomenclature. Annals of the rheumatic diseases 71: 1437–1439.
Mason T, Reed AM, Nelson AM, Thomas KB (2005) Radiographic progression in children with polyarticular juvenile rheumatoid arthritis: a pilot study. Ann Rheum Dis 64: 491–493
Moore TL (1999) Immunopathogenesis of juvenile rheumatoid arthritis. Curr Opin Rheumatol 11: 377–383
Murray KJ, Lovell DJ (2002) Advanced therapy for juvenile arthritis. Best Pract Res Clin Rheumatol 16: 361–378
Nistala K, Moncrieffe H, Newton KR, Varsani H, Hunter P, Wedderburn LR (2008) Interleukin-17-producing T cells are enriched in the joints of children with arthritis, but have a reciprocal relationship to regulatory T cell numbers. Arthritis Rheum 58: 875–887
Oen K, Reed M, Malleson PN, Cabral DA, Petty RE, Rosenberg AM, Cheang M (2003) Radiologic outcome and its relationship to functional disability in juvenile rheumatoid arthritis. J Rheumatol 30: 832–840
Olsen NJ, Stein CM (2004) New drugs for rheumatoid arthritis. N Engl J Med 350: 2167–2179
Packham JC, Hall MA (2002a) Long-term follow-up of 246 adults with juvenile idiopathic arthritis: social function, relationships and sexual activity. Rheumatology (Oxford) 41: 1440–1443
Packham JC, Hall MA (2002b) Long-term follow-up of 246 adults with juvenile idiopathic arthritis: education and employment. Rheumatology (Oxford) 41: 1436–1439
Padeh S, Passwell JH (1998) Intraarticular corticosteroid injection in the management of children with chronic arthritis. Arthritis Rheum 41: 1210–1214
Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, He X, Maldonado-Cocco J, Orozco-Alcala J, Prieur AM, Suarez-Almazor ME, Woo P (2004) International League of Associations for Rheumatology Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 31: 390–392
Prahalad S, Glass D (2008) A comprehensive review of the genetics of juvenile idiopathic arthritis. Pediatric Rheumatology 6: 11
Prakken B, Kuis W, van Eden W, Albani S (2002) Heat shock proteins in juvenile idiopathic arthritis: keys for understanding remitting arthritis and candidate antigens for immune therapy. Curr Rheumatol Rep 4: 466–473
Ravelli A, Viola S, Ramenghi B, Aramini L, Ruperto N, Martini A (1995) Frequency of relapse after discontinuation of methotrexate therapy for clinical remission in juvenile rheumatoid arthritis. J Rheumatol 22: 1574–1576
Ravelli A, Varnier GC, Oliveira S, Castell E, Arguedas O, Magnani A, Pistorio A, Ruperto N, Magni-Manzoni S, Galasso R, Lattanzi B, Dalprà S, Battagliese A, Verazza S, Allegra M, Martini A (2011) Antinuclear antibody-positive patients should be grouped as a separate category in the classification of juvenile idiopathic arthritis. Arthritis Rheum 63: 267–75
Rosen P, Thompson S, Glass DN (2003) Non-HLA gene polymorphisms in juvenile rheumatoid arthritis. Clin Exp Rheumatol 21: 650–656
Ruperto N, Murray KJ, Gerloni V, Wulffraat N, de Oliveira SK, Falcini F, Dolezalova P, Alessio M, Burgos-Vargas R, Corona F, Vesely R, Foster H, Davidson J, Zulian F, Asplin L, Baildam E, Consuegra JG, Ozdogan H, Saurenmann R, Joos R, Pistorio A, Woo P, Martini A (2004) A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate. Arthritis Rheum 50: 2191–2201
Ruperto N, Nikishina I, Pachanov ED, Shachbazian Y, Prieur AM, Mouy R, Joos R, Zulian F, Schwarz R, Artamonova V, Emminger W, Bandeira M, Buoncompagni A, Foeldvari I, Falcini F, Baildam E, Kone-Paut I, Alessio M, Gerloni V, Lenhardt A, Martini A, Hanft G, Sigmund R, Simianer S (2005) A randomized, double-blind clinical trial of two doses of meloxicam compared with naproxen in children with juvenile idiopathic arthritis: short- and long-term efficacy and safety results. Arthritis Rheum 52: 563–572
Ruperto N, Lovell DJ, Cuttica R, Wilkinson N, Woo P, Espada G, Wouters C, Silverman ED, Balogh Z, Henrickson M, Apaz MT, Baildam E, Fasth A, Gerloni V, Lahdenne P, Prieur AM, Ravelli A, Saurenmann RK, Gamir ML, Wulffraat N, Marodi L, Petty RE, Joos R, Zulian F, McCurdy D, Myones BL, Nagy K, Reuman P, Szer I, Travers S, Beutler A, Keenan G, Clark J, Visvanathan S, Fasanmade A, Ray-Chaudhuri A, Mendelsohn A, Martini A, Giannini EH (2007) A randomized, placebo- controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum 56: 3096–3106
Ruperto N, Lovell DJ, Quartier P, Paz E, Rubio-Perez N, Silva CA, Abud- Mendoza C, Burgos-Vargas R, Gerloni V, Melo-Gomes JA, Saad- Magalhaes C, Sztajnbok F, Goldenstein- Schainberg C, Scheinberg M, Penades IC, Fischbach M, Orozco J, Hashkes PJ, Hom C, Jung L, Lepore L, Oliveira S, Wallace CA, Sigal LH, Block AJ, Covucci A, Martini A, Giannini EH (2008) Abatacept in children with juvenile idiopathic arthri- tis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet 372: 383–391
Ruperto N, Lovell DJ, Quartier P, Paz E, Rubio-Perez N, Silva CA, Abud- Mendoza C, Burgos-Vargas R, Gerloni V, Melo-Gomes JA, Saad- Magalhaes C, Chavez-Corrales J, Huemer C, Kivitz A, Blanco FJ, Foeldvari I, Hofer M, Horneff G, Huppertz HI, Job-Deslandre C, Loy A, Minden K, Punaro M, Nunez AF, Sigal LH, Block AJ, Nys M, Martini A, Giannini EH (2010) Long-term safety and efficacy of abatacept in children with juvenile idiopathic arthritis. Arthritis Rheum 62: 1792–1802
Sailer M, Cabral D, Petty RE, Malleson PN (1997) Rheumatoid factor positive, oligoarticular onset juvenile rheumatoid arthritis. J Rheumatol 24: 586–588
Schmeling H, Mathony K, John V, Keysser G, Burdach S, Horneff G (2001) A combination of etanercept and methotrexate for the treatment of refractory juvenile idiopathic arthritis: a pilot study. Ann Rheum Dis 60: 410–412
Silverman E, Mouy R, Spiegel L, Jung LK, Saurenmann RK, Lahdenne P, Horneff G, Calvo I, Szer IS, Simpson K, Stewart JA, Strand V, the Leflunomide in Juvenile Rheumatoid Arthritis (JRA) Investigator Group (2005) Leflunomide or Methotrexate for Juvenile Rheumatoid Arthritis. N Engl J Med 352: 1655–1666
Thomas E, Symmons DP, Brewster DH, Black RJ, Macfarlane GJ (2003) National study of cause-specific mortality in rheumatoid arthritis, juvenile chronic arthritis, and other rheumatic conditions: a 20 year followup study. J Rheumatol 30: 958–965
Thompson SD, Grom AA, Bailey S, Luyrink L, Giannini EH, Murray K, Passo MH, Lovell DJ, Choi E, Glass DN (1995) Patterns of T lymphocyte clonal expansion in HLA-typed patients with juvenile rheumatoid arthritis. J Rheumatol 22: 1356–1364
Thompson SD, Moroldo MB, Guyer L, Ryan M, Tombragel EM, Shear ES, Prahalad S, Sudman M, Keddache MA, Brown WM, Giannini EH, Langefeld CD, Rich SS, Nichols WC, Glass DN (2004) A genomewide scan for juvenile rheumatoid arthritis in affected sibpair families provides evidence of linkage. Arthritis Rheum 50: 2920–2930
Tynjälä P, Vähäsalo P, Tarkiainen M, Kröger L, Aalto K, Malin M, Putto- Laurila A, Honkanen V, Lahdenne P (2011) Aggressive Combination Drug Therapy in Very Early Polyarticular Juvenile Idiopathic Arthritis (ACUTE–JIA): a multicentre randomised open-label clinical trial. Ann Rheum Dis 70: 1605–1612
Van Rossum MA, Fiselier TJ, Franssen MJ, Zwinderman AH, ten Cate R, van Suijlekom-Smit LW, van Luijk WH, van Soesbergen RM, Wulffraat NM, Oostveen JC, Kuis W, Dijkstra PF, van Ede CF, Dijkmans BA (1998) Sulfasalazine in the treatment of juvenile chronic arthritis: a randomized, double-blind, placebo-controlled, multicenter study. Dutch Juvenile Chronic Arthritis Study Group. Arthritis Rheum 41: 808–816
Van Rossum M, Van Soesbergen R, De Kort S, Ten Cate R, Zwinderman AH, De Jong B, Dijkmans B (2003) Anti-cyclic citrullinated peptide (anti-CCP) antibodies in children with juvenile idiopathic arthritis. J Rheumatol 30: 825–828
Verbsky JW, White AJ (2004) Effective use of the recombinant interleukin 1 receptor antagonist anakinra in therapy resistant systemic onset juvenile rheumatoid arthritis. J Rheumatol 31: 2071–2075
Wallace CA, Giannini EH, Spalding SJ, Hashkes PJ, O›Neil KM, Zeft AS, Szer IS, Ringold S, Brunner HI, Schanberg LE, Sundel RP, Milojevic D, Punaro MG, Chira P, Gottlieb BS, Higgins GC, Ilowite NT, Kimura Y, Hamilton S, Johnson A, Huang B, Lovell DJ; for the Childhood Arthritis and Rheumatology Research Alliance (2012) Trial of Early Aggressive Therapy in Polyarticular Juvenile Idiopathic Arthritis. Arthritis Rheum 64: 2012–2021
Wedderburn LR, Robinson N, Patel A, Varsani H, Woo P (2000) Selective recruitment of polarized T cells expressing CCR5 and CXCR3 to the inflamed joints of children with juvenile idiopathic arthritis. Arthritis Rheum 43: 765–774
Yokota S, Imagawa T, Mori M, Miyamae T, Aihara Y, Takei S, Iwata N, Umebayashi H, Murata T, Miyoshi M, Tomiita M, Nishimoto N, Kishimoto T (2008) Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, doubleblind, placebo-controlled, withdrawal phase III trial. Lancet 371: 998–1006
Zulian F, Martini G, Gobber D, Plebani M, Zacchello F, Manners P (2004) Triamcinolone acetonide and hexacetonide intra-articular treatment of symmetrical joints in juvenile idiopathic arthritis: a double- blind trial. Rheumatology (Oxford) 43: 1288–1291
Literatur zu Kap. 4.7
Amor B, Dougados M, Mijiyawa M (1990) Criteria of the classification of spondylarthropathies. Rev Rhum Mal Osteoartic 57: 85–89
Amor B, Dougados M, Listrat V et al. (1991) Evaluation of the Amor criteria for spondylarthropathies and European Spondylarthropathy Study Group (ESSG). A cross-sectional analysis of 2.228 patients. Ann Med Interne (Paris) 142: 85–89
Andersson Gare B (1999) Juvenile arthritis – who gets it, where and when? A review of current data on incidence and prevalence. Clin Exp Rheumatol 17: 367–374
Bennett, Wood (1968) Population studies of the rheumatic diseases. Excerpta Medica, New York, pp 4–6
Boiu S, Marniga E, Bader.Meunier B, et al. (2012) functional status in severe juvenile arthritis in the biologic treatment era: an assessment in a French paediatric rheumatology referral centre. Rheumatology 51:1285–1295
Brooks CD (2001) Sulfasalazine for the management of juvenile rheumatoid arthritis. J Rheumatol 28: 845–853
Burgos-Vargas R (1993) Spondyloarthropathies and psoriatic arthritis in children. Curr Opin Rheumatol 5: 634–643
Burgos-Vargas R, Pacheco-Tena C, Vazquez-Mellado J (1997) Juvenileonset spondyloarthropathies. Rheum Dis Clin North Am 23: 569–598
Burgos-Vargas R, Vazquez-Mellado J, Pacheco-Tena C, Hernandez-Garduno A, Goycochea-Robles MV (2002) A 26 week randomised, double blind, placebo controlled exploratory study of sulfasalazine in juvenile onset spondyloarthropathies. Ann Rheum Dis 61: 941–942
Burgos-Vargas R, Casasola-Vargas J, Gutierrez-Suarez R (2008) A 3-month, double-blind, placebo-controlled, randomized trial of infliximab in juvenile-onset spondyloarthritis (SpA) and a 52-week open extension. Clin Exp Rheumatol 26: 745
Cabral DA, Malleson PN, Petty RE (1995) Spondyloarthropathies of childhood. Pediatr Clin North Am 42: 1051–1070
Cassidy JT, Petty RE (2001) Juvenile ankylosing spondylitis. In: Cassidy JT, Petty RE (eds) Textbook of pediatric rheumatology. Saunders, Philadelphia, pp 323–345
Colbert RA (2010) Classification of juvenile spondyloarthritis: enthesitis- related arthritis and beyond. Nat Rev Rheumatol 6(8):477–485
Dougados M, van der Linden S, Juhlin R et al. (1991) The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum 34: 1218–1227
Ebringer A, Wilson C (2000) HLA molecules, bacteria and autoimmunity. J Med Microbiol 49: 305–311
Flato B, Aasland A, Vinje O, Forre O (1998) Outcome and predictive factors in juvenile rheumatoid arthritis and juvenile spondyloarthropathy. J Rheumatol 25: 366–375
Grom AA, Murray KJ, Luyrink L et al. (1996) Patterns of expression of tumor necrosis factor alpha, tumor necrosis factor beta, and their receptors in synovia of patients with juvenile rheumatoid arthritis and juvenile spondylarthropathy. Arthritis Rheum 39: 1703–10
Henrickson M, Reiff A (2004) Prolonged efficacy of etanercept in refractory enthesitis-related arthritis. J Rheumatol 31: 2055–2061
Huppertz HI, Sandhage K (1994) Reactive arthritis due to Salmonella enteritidis complicated by carditis. Acta Paediatr 83: 1230–1231
Imundo LF, Jacobs JC (1996) Sulfasalazine therapy for juvenile rheumatoid arthritis. J Rheumatol 23: 360–366
May E, Dulphy N, Frauendorf E et al. (2002) Conserved TCR beta chain usage in reactive arthritis; evidence for selection by a putative HLA-B27-associated autoantigen. Tissue Antigens 60: 299–308
Minden K, Niewerth M, Listing J et al. (2002) Long-term outcome in patients with juvenile idiopathic arthritis. Arthritis Rheum 46: 2392–2401
Myles A, Aggarwal A (2011) Expression of Toll-like receptors 2 and 4 is increased in peripheral blood and synovial fluid monocytes of patients with enthesitis-related arthritis subtype of juvenile idiopathic arthritis. Rheumatology 50:481–488
Myles A, Rehmann MT, Aggarwal A (2012) Membrane bound toll-like receptors are overexpressed in peripheral blood and synovial fluid mononuclear cells of enthesitis-related arthritis (JIA-ERA) patients and lead to secretion of inflammatory mediators. J Clin Immunol 32: 488–496
Otten MH, Prince FHM, Twilt M, Cate R ten, Armbrust W, Hoppenreijs EPAH, Koopman-Keemink Y, Wulffraat NM, Gorter SL, Dolman KM, Swart JF, van den Berg JM, van Rossum MAJ, van Suijlekom-Smit LWA (2011) Tumor necrosis factor-blocking agents for children with enthesitis-related arthritis–data from the dutch arthritis and biologicals in children register, 1999-2010. The Journal of rheumatology 38: 2258–2263
Petty RE, Southwood TR, Baum J et al. (1998) Revision of the proposed classification criteria for juvenile idiopathic arthritis: Durban, 1997. J Rheumatol 25: 1991–1994
Petty RE, Southwood TR, Manners P et al. (2004) International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: 2nd rev, Edmonton. J Rheumatol 31: 390–392
Rosenberg AM, Petty RE (1982) A syndrome of seronegative ethesopathy and arthropathy in children. Arthritis Rheum 25:1041–1047
Selvaag AM, Lien G, Sorskaar D, Vinje O, Forre O, Flato B (2005) Early disease course and predictors of disability in juvenile rheumatoid arthritis and juvenile spondyloarthropathy: a 3 year prospective study. J Rheumatol 32: 1122–1130
Sherlock JP, Joyce-Shaikh B, Turner SP et al. (2012) IL-23 induces spondylarthropathy by acting on ROR-yt+ CD3+CD4-CD8- enthesial resident T cells. Nat Med 18:1069–1076
Sieper J, Braun J (2002) Anti-TNF agents for the treatment of spondyloarthropathies. Expert Opin Emerg Drugs 7: 235–246
Stamato T, Laxer RM, de Freitas C et al. (1995) Prevalence of cardiac manifestations of juvenile ankylosing spondylitis. Am J Cardiol 75: 744–746
Stone M, Warren RW, Bruckel J, Cooper D, Cortinovis D, Inman RD (2005) Juvenile-onset ankylosing spondylitis is associated with worse functional outcomes than adult-onset ankylosing spondylitis. Arthritis Rheum 53: 445–451
Tse SML, Burgos-Vargas R, Colbert RA (2012) Juvenile spondyloarthritis treatment recommendations. The American journal of the medical sciences 343: 367–370
Van der Heijde D, Sieper J, Maksymowych WP (2011) 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. Ann Rheum Dis 70:905–908
Van Rossum MA, Fiselier TJ, Franssen MJ et al. (1998) Sulfasalazine in the treatment of juvenile chronic arthritis: a randomized, doubleblind, placebo-controlled, multicenter study. Dutch Juvenile Chronic Arthritis Study Group. Arthritis Rheum 41: 808–816
Van Rossum MA, Fiselier TJ, Franssen MJ et al. (2001) Effects of sulfasalazine treatment on serum immunoglobulin levels in children with juvenile chronic arthritis. Scand J Rheumatol 30: 25–30
Van Rossum MA, Zwinderman AH, Boers M et al. (2003) Radiologic features in juvenile idiopathic arthritis: a first step in the development of a standardized assessment method. Arthritis Rheum 48: 507–515
Varbanova BB, Dyankov ED (1999) Sulphasalazine. An alternative drug for second-line treatment of juvenile chronic arthritis. Adv Exp Med Biol 455: 331–336
Viswanath V, Myles A, Dayal R, Aggarwal A (2011) Levels of serum matrix metalloproteinase-3 correlate with disease activity in enthesitis- related arthritis category of juvenile idiopathic arthritis JIA. J Rheumatol 38: 2482–2487
Weiss PF, Beukelman T, Schanberg LE, et al. (2012) Enthesitis-related Arthritis is associated with higher pain intensity and poorer health status in comparison with other categories of juvenile idiopathic arthritis: The childhood arthritis and rheumatology research alliance registry. J Rheumatol [Epub]
Wilson C, Rashid T, Tiwana H et al. (2003) Cytotoxicity responses to peptide antigens in rheumatoid arthritis and ankylosing spondylitis. J Rheumatol 30: 972–978
Literatur zu Kap. 4.8
Abu-Shakra M, Gladman DD, Thorne JC et al. (1995) Long-term methotrexate therapy in psoriatic arthritis: clinical and radiological outcome. J Rheumatol 22
Ash Z, Gaujoux-Viala, C, Gossec L et al. (2012) A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis. Ann Rheum Dis 71
Ansell BM, Rudge S, Schaller JG (1991) A colour atlas of paediatric rheumatology. Mosby-Wolfe, London
Antoni C, Dechant C, Hanns-Martin Lorez PD et al. (2002) Open-label study of infliximab treatment for psoriatic arthritis: clinical and magnetic resonance imaging measurements of reduction of inflammation. Arthritis Rheum 47
Antoni CE, Kavanaugh A, Gladman DD et al. (2004) The Infliximab multinational psoriatic arthritis controlled trial (IMPACT): results of radiographic analyses after 1 year. Arthritis Rheum 50 (Suppl)
Bernston L, Fasth A, Andersson-Gäre B et al. (2001) Construct validity of ILAR and EULAR criteria in juvenile idiopathic arthritis: a population based incidence study from the Nordic countries. J Rheumatol 28
Bowyer S, Roettcher P, members of the Pediatric Rheumatology Database Research Group (1996) Pediatric rheumatology clinic populations in the United States: results of a 3 year survey. J Rheumatol 23
Brandt J, Haibel H, Cornely D et al. (2000) Successful treatment of ankylosing spondylitis. with the anti-tumor necrosis factor alpha monoclonal antibody infliximab. Arthritis Rheum 43
Butbul YA, Tyrrell PN, Schneider R, Dhillon S et al. (2009) Comparison of patients with juvenile psoriatic arthritis and nonpsoriatic juvenile idiopathic arthritis: how different are they ? J Rheumatol 36
Calabro JJ (1977) Psoriatic arthritis in children. Arthritis Rheum 20 (Suppl)
Chang JC, Smith LR, Froning KJ et al. (1997) Persistence of T cell clones in psoriatic lesions. Arch Dermatol 133
Costello P, Bresnihan B, O’Farrelly C, Fitzgerald O (1999) Predominance of CD8+ T lymphocytes in psoriatic arthritis. J Rheumatol 26
Cuellar ML, Espinoza LR (1997) Methotrexate use in psoriasis and psoriatic arthritis. Rheum Dis Clin North Am 23
Day TG, Ramanan AV, Hinks A et al. (2008) Autoinflammatory genes and susceptibility to psoriatic juvenile idiopathic arthritis Arthritis Rheum 58
Dougados M, van der Linden S, Juhlin R et al. (1991) The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum 34
Eldar JT, Henseler T, Christophes E et al. (1994) Of genes and antigens. The genetics of psoriasis. J Invest Dermatol 1 (Suppl)
Ellis CN, Fradin MS, Messana JM et al. (1991) Cyclosporin for plaquetype psoriasis. Results of a multidose, double-blind trial. N Engl J Med 324
Espinoza LR, Zakkraoni L, Espinoza CG et al. (1992) Psoriatic arthritis clinical response and side effects of methotrexate therapy. J Rheumatol 19
Fantini F (2001) Classification of chronic arthritides in childhood (juvenile idiopathic arthritis): criticisms and suggestions to improve the efficacy of the Santiago-Durban criteria. J Rheumatol 28
Farber EM, Nall L (1999) Childhood psoriasis. Cutis 64
Flato B, Lien G, Smerdel-Ramoya A et al. (2009) Juvenile psoriatic arthritis: longterm outcome and differentiation form other subtypes of juvenile idiopathic arthritis. J Rheumatol 36
Foeldvari I, Bidde M (2000) Validation of the proposed ILAR classification criteria for juvenile idiopathic arthritis. J Rheumatol 27
Fuchs BS, Hadi Suhail (2006) Use of etanercept in the treatment of psoriasis and psoriatic arthritis. Reviews on Recent Clinical Trials 1
Gare BA, Fasth A (1992) Epidemiology of juvenile chronic arthritis in southwestern Sweden: a 5-year prospective population study. Pediatrics 90
Gladman DD, Anhorn KA, Schachter RK, Mervart H (1986) HLA antigens in psoriatic arthritis. J Rheumatol 13
Gladman DD, Farewell VT, Kopciuk A, Cook RJ (1998) HLA markers and progression in psoriatic arthritis. J Rheumatol 25
Gottlieb SL, Gilleaudeau P, Johnson R et al. (1995) Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune but not keratinocyte, pathogenic basis. Nat Med 1
Harrison BJ, Silman AJ, Barrett EM et al. (1997) Presence of psoriasis does not influence the presentation or short-term outcome of patients with early inflammatory polyarthritis. J Rheumatol 24
Hinks A, Martin P, Flynn E et al. (2011) Subtype specific genetic associations for juvenile idiopathic arthritis: ERAP1 with the enthesitis related arthritis subtype and IL23R with juvenile psoriatic arthritis. Arthritis Research & Therapy 13
Hofer MF, Mouy R, Prieur A-M (2000) Juvenile idiopathic arthritides evaluated prospectively in a single center according to the Durban criteria. J Rheumatol 28
Huemer C, Malleson PN, Cabral DA et al. (2002) Patterns of joint involvement at onset differentiate oligoarticular juvenile psoriatic arthritis from pauciarticular juvenile rheumatoid arthritis. J Rheumatol 29
Konig A, Krenn V, Gillitzer R et al. (1997) Inflammatory infiltrate and interleukin- 8 expression in the synovium of psoriatic arthritis- an immunohistochemical and mRNA analysis. Rheumatol Int 17
Kruithof E, Van den Bosch F, Baeten D et al. (2002) Repeated infusions of infliximab, a chimeric anti-TNFalpha monoclonal antibody, in patients with active spondylarthropathy: one year follow up. Ann Rheum Dis 61
Krumrey- Langkammerer M, Hafner R (2002) Evaluation of the ILAR criteria for juvenile idiopathic arthritis. J Rheumatol 28
Langevitz P, Buskila D, Gladman DD (1990) Psoriatic arthritis precipitated by physical trauma. J Rheumatol 17
Lee EY, Sundel RP, Kim S et al. (2008) MRI findings of juvenile psoriatic arthritis Skeletal Radiol 37
Malleson PN, Fung MY, Rosenberg AM (1996) The incidence of pediatric rheumatic diseases: results from the Canadian Pediatric Rheumatology Association Disease Registry. J Rheumatol 23
Manners P, Lesslie J, Speldewinde D, Tunbridge D (2003) Classification of juvenile idiopathic arthritis: Should family history be included in the criteria ? J Rheumatol 30:8
Marsal S, Armadens-Gil L, Martinez M et al. (1999) Clinical radiographic and HLA associations as markers for different patterns of psoriatic arthritis. Rheumatology 38
Mease P, Kavanaugh A, Krueger G et al. (2004) Infliximab improves psoriasis regardless of arthritis response in patients with active psoriatic arthritis: results from the IMPACT 2 trial. Arthritis Rheum 50 (Suppl)
Mease PJ, Goffe BS, Metz J, Vanderstoep A, Finck B et al. (2000) Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomized trial. Lancet 356
Moll JM, Wright V (1973) Psoriatic arthritis. Semin Arthritis Rheum 3: 55
Murray KJ, Grom AA, Thompson SD et al. (1998) Contrasting cytokine profiles in the synovium of different forms of juvenile rheumatoid arthritis and juvenile spondylarthropathy: prominence of interleukin 4 in restricted disease. J Rheumatol 25
Nickoloff BJ, Mitra RS, Sailer D et al. (1994) Aberrant production of interleukin- 8 and thrombospondin-1 by psoriatic keratinocytes mediates angiogenesis. Am J Pathol 144
Oen K, Fast M, Postl B (1995) Epidemiology of juvenile rheumatoid arthritis in Manitoba, Canada, 1975–1992: cycles in incidence. J Rheumatol 22
Olivieri I, Salvarani C, Cantini F et al. (1997) Therapy with cyclosporin in psoriatic arthritsi. Semin Arthritis Rheum 27
Otten MH, Prince FH, Cate RT et al. (2011) Tumour necrosis factorblocking agents in juvenile psoriatic arhritis: are they effective? Ann Rheum Dis 70
Partsch G, Wagner E, Leeb BF et al. (1998) Upregulation of cytokine receptors sTNF-R55, sTNF-R75, and sIL-2R in psoriatic arthritis synovial fluid. J Rheumatol 25
Paukkonnen K, Naukkarinen A, Horstmanheimo M (1992) The development of manifest psoriatic lesions is linked with the invasion of CD8+ cells and CD11c+ macrophages into the epidermis. Arch Dermatol Res 284
Petty RE, Southwood TR, Baum J et al. (1998) Revision of the proposed classification criteria for juvenile idiopathic arthritis: Durban 1997. J Rheumatol 25: 10
Petty RE, Southwood TR, Manners P et al. (2004) International League of Associations for Rheumatology Classification of Juvenile Idiopathic Arthritis: Second Revision, Edmonton 2001. J Rheumatol 31:2
Punzi L, Pianon M, Bertazzolo N et al. (1998) Clinical laboratory and immunogenetic aspects of post-traumatic psoriatic arthritis: a study of 25 patients. Clin Exp Rheumatol 16
Ramsey SE, Bolaria RK, Cabral DA, Malleson PN, Petty RE (2000) Comparison of criteria for the classification of childhood arthritis. J Rheumatol 27: 5
Reece RJ, Canete JD, Parsons WJ et al. (1999) Distinct vascular patterns of early synovitis in psoriatic, reactive and rheumatoid arthritis. Arthritis Rheum 42
Ritchlin C, Hass-Smith SA, Hicks D et al. (1998) Patterns of cytokine production in psoriatic synovium. J Rheumatol 25
Roberton DM, Cabral DA, Malleson PN, Petty RE (1996) Juvenile psoriatic arthritis: follow-up and evaluation of diagnostic criteria. J Rheumatol 23
Salvarani C, Cantini F, Olivieri I et al. (1997) Isolated peripheral enthesitis and/or dactylitis: a subset of psoriatic arthritis. J Rheumatol 24
Southwood TR, Petty RE, Malleson PN et al. (1989) Psoriatic arthritis in children. Arthritis Rheum 32: 1007
Spadaro A, Taccari E, Mohtadi B et al. (1997) Life-table analysis of cyclosporin A treatment in psoriatic arthritis: comparison with other disease-modifying antirheumatic drugs. Clin Exp Rheumatol 15
Sticherling M, Minden K, Küster RM et al. (2007) Psoriasis und Psoriasisarthritis im Kindes – und Jugendalter. Zeitschrift für Rheumatol 4
Stoll ML, Lio P, Sundel RP et al. (2008) Comparison of Vancouver and ILAR Classification criteria for juvenile psoriatic arthritis. Arthritis Rheum 59
Stoll ML, Zurakowski D, Nigrovic LE et al. (2006) Patients with juvenile psoriatic arthritis comprise two distinct populations. Arthritis Rheum 54
Stoll ML, Nigrovic PA (2011) Clinical comparison of early-onset psoriatic and non-psoriatic oligoarticular juvenile idiopathic arthritis. Clin Exp Rheumatol 29
Symmons DPM, Jones M, Osborne J et al. (1996) Pediatric rheumatology in the United Kingdom: data from the British Paediatric Rheumatology Group National Diagnostic Register. J Rheumatol 23
Telfer NR, Chalmers RJ, Whale K, Colman G (1992) The role of streptococcal infection in the initiation of guttate psoriasis. Arch Dermatol 128
Tomfohrde J, Silverman A, Barnes R et al. (1994) Gene for familial psoriasis susceptibility mapped to the distal end of human chromosome 17q. Science 264
Van den Bosch F, Kruithof E, Baeten D, De Keyser F, Mielants H, Veys EM (2000) Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondylarthropathy: an open pilot study. Ann Rheum Dis 59
Vasey FB, Seleznick MJ, Fenske NA, Espinoza LR (1989) New sign-posts on the road to understanding psoriatic arthritis. J Rheumatol 16
Vasey FB, Deitz C, Fenske NA et al. (1982) Possible involvement of group A streptococci in the pathogenesis of psoriatic arthritis. J Rheumatol 9
Weinblatt ME, Keystone EC, Furst DE et al. (2003) Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate. The ARMADA trial. Arthritis Rheum 48
Wong WM, Howell WM, Coy SD et al. (1996) Interleukin-2 is found in the synovium of psoriatic arthritis and spondyloarthritis, not in rheumatoid arthritis. Scand J Rheumatol 25
Literatur zu Kap. 4.9
Biester S, Deuter C, Michels H et al. (2007) Adalimumab in the therapy of uveitis in childhood. Br J Ophthalmol 91:319–324
Bhat P, Castaneda R et al (2009) Intravenous daclizumab for recalcitrant ocular inflammatory disease. Graefes Arch Clin Exp Ophthalmol 247:687–692
Bloch-Michel E, Nussenblatt RB (1976) International Uveitis Study Group recommendations for the evaluation of intraocular inflammatory disease. Am J Ophthalmol 103: 234–235
Bosch-Driessen LE, Berendschot TT et al. (2002) Ocular toxoplasmosis: Clinical features and prognosis of 154 patients. Ophthalmology 109: 869–878
Cabral DA, Petty RE et al. (1994) Visual prognosis in children with chronic anterior uveitis and arthritis. J Rheumatol 21: 2370–2375
Carvounis PE, Herman DC, Cha S et al. (2006) Incidence and outcomes of uveitis in juvenile rheumatoid arthritis, a synthesis of the literature. Graefe’s Arch Clin Exp Ophthalmol 244:281–290
Cassidy JT, Sullivan DB et al. (1977) Clinical patterns of chronic iridocyclitis in children with juvenile rheumatoid arthritis. Arthritis Rheum 20 (Suppl): 224–227
Chalom EC, Goldsmith DP et al. (1997) Prevalence and outcome of uveitis in a regional cohort of patients with juvenile rheumatoid arthritis. J Rheumatol 24: 2031–2034
Dana MR, Merayo-Lloves J et al. (1997) Visual outcomes prognosticators in juvenile rheumatoid arthritis-associated uveitis. Ophthalmology 104: 236–244
Edelsten C, Lee V et al. (2002) An evaluation of baseline risk factors predicting severity in juvenile idiopathic arthritis associated uveitis and other chronic anterior uveitis in early childhood. Br J Ophthalmol 86: 51–56
Edelsten C, Reddy MA et al. (2003) Visual loss associated with pediatric uveitis in english primary and referral centers. Am J Ophthalmol 135: 676–680
El-Shabrawi Y, Hermann J (2002) Anti-tumor necrosis factor-alpha therapy with infliximab as an alternative to corticosteroids in the treatment of human leukocyte antigen B27-associated acute anterior uveitis. Ophthalmology 109: 2342–2346
Fan DS, Yu CB, Chiu TY et al. (2003) Ocular-hypertensive and anti-inflammatory response to rimexolone therapy in children. Arch Ophthalmol 121:1716–1721
Foeldvari I, Wierk A (2005) Methotrexate is an effective treatment for chronic uveitis associated with juvenile idiopathic arthritis. J Rheumatol 32:362–365
Foeldvari I, Nielsen S, Kummerle-Deschner J et al. (2007) Tumor necrosis factor-alpha blocker in treatment of juvenile idiopathic arthritis- associated uveitis refractory to second-line agents: results of a multinational survey. J Rheumatol 34:1146–1150
Foster CS, Barrett F (1993) Cataract development and cataract surgery in patients with juvenile rheumatoid arthritis-associated iridocyclitis. Ophthalmology 100: 809–817
Gerloni V, Cimaz R, Gattinara M et al. (2001) Efficacy and safety profile of cyclosporin A in the treatment of juvenile chronic (idiopathic) arthritis. Results of a 10-year prospective study. Rheumatology (Oxford) 40:907–913
Goebel J, Rosel M, Heinz C, Michels H, Ganser G, Heiligenhaus A (20011) Azathioprine as a treatment option for uveitis in patients with juvenile idiopathic arthritis. Br J Ophthalmol 95:209–213
Godfrey WA, Lindsley CB, Cuppage FE (1981) Localization of IgM in plasma cells in the iris of a patient with iridocyclitis and juvenile rheumatoid arthritis. Arthritis Rheum 24: 1195–1198
Grajewski R, Zurek.Imhoff B, Rösel M, Heinz C, Heiligenhaus A (2011) Favourable outcome after cataract surgery with IOL implantation in uveitis associated with juvenile idiopathic arthritis. Acta Ophthalmol [Epub ahead of print]
Heiligenhaus A, Mingels A et al. (2003) Juvenile idiopathic arthritis and uveitis: Screening and anti-inflammatory therapy. Klin Monatsbl Augenheilkd 220: 738–753
Heiligenhaus A, Niewerth M et al. (2005) Epidemiologische Daten zur Uveitis bei juveniler idiopathischer Arthritis aus einer bundesweiten pädiatrischen und ophthalmologischen Datenerhebung (Uveitis-Modul der Kerndokumentation). Klin Monatsbl Augenheilk 222: 993ff
Heiligenhaus A, Mingels A, Heinz C et al. (2007) Methotrexate for uveitis associated with juvenile idiopathic arthritis: value and requirement for additional anti-inflammatory medication. Eur J Ophthalmol 17:743–748
Heiligenhaus A, Niewerth M, Ganser G, Heinz C, Minden K and German Uveitis in Childhood Study Group (2007) Prevalence and complications of uveitis in juvenile idiopathic arthritis in a population based nation-wide study in Germany: suggested modification of the current screening guidelines. Rheumatology 46:1015–1019
Heiligenhaus A, Thurau S, Hennig M, Grajewski R, Wildner G (2010) Anti- inflammatory treatment of uveitis with biologicals: new treatment options that reflect pathogenetic knowledge of the disease. Graefes Arch Clin Exp Ophthalmol 248: 1531–1551
Heiligenhaus A, Michels H et al. (2011) Evidenced-based, interdisciplinary guidelines for anti-inflammatory treatment of uveitis associated with juvenile idiopathic arthritis. Rheumatol Int [Epub ahead of print]
Heiligenhaus A, Miserocchi E et al. (2011) Treatment of severe uveitis associated with juvenile idiopathic arthritis with anti-CD20 monoclonal antibody (rituximab). Rheumatology 50: 1390–1394
Heinz C, Koch JM, Heiligenhaus A (2006) Transcleral diode laser cyclophotocoagulation as primary surgical treatment for secondary glaucoma in juvenile idiopathic arthritis: high failure rate after short term follow up. Br J Ophthalmol 90: 737–740
Heinz C, Mingels A, Goebel C, Fuchsluger T, Heiligenhaus A (2008) Chronic uveitis in children with and without juvenile idiopathic arthritis: differences in patient characteristics and clinical course. J Rheumatol 35: 1403–1407
Heinz C, Pleyer U, Ruokonnen P, Heiligenhaus A (2008) Secondary glaucoma in childhood uveitis. Ophthalmologe 105: 438–444
Heinz C, Schuamcher C, Roesel M, Heiligenhaus A (2012) Elevated intraocular pressure in uveitis accociated with juvenile idiopathic arthritis- associated uveitis, often detected after acchieving inactivity. Br J Ophthalmol 96: 140–141
Heinz C, Heiligenhaus A et al. (2011) Uveitis bei juveniler idiopathischer Arthritis. Z Rheumatol 69: 411–418
Heinz C, Koch JM; Heiligenhaus A (2011) Trabeculectomy or modified deep sclerectomy in juvenile uveitis glaucoma. J Ophthalmic Inflamm Infect 1; 165–170
Hemady RK, Baer JC, Foster CS (1992) Immunosuppressive drugs in the management of progressive, corticosteroid-resistant uveitis associated with juvenile rheumatoid arthritis. Int Ophthalmol Clin 32: 241–252
Hinzpeter EN, Naumann G, Bartelheimer HK (1971) Ocular histopathology in Still’s disease. Ophthalmic Res 2: 16–24
Jabs DA, Nussenblatt RB, Rosenbaum JT (2005) Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol 140:509–516
Kalinina Avuso V, ten Cate HA, van der Does P, Rothova A, de Boer JH (2010) Male gender as a risk factor for complications in uveitis associated with juvenile idiopathic arthritis. Am J Ophthalmol 149: 994–999
Kalinina Avaso V, van de Winkel EL, Rothova A, de Boer JH (2011) Relapse rate of uveitis post-methotrexate treatment in juvenile idiopathic arthritis. Am J Ophthalmol 151: 217–222
Kanski JJ (1988) Uveitis in juvenile chronic arthritis: Incidence, clinical features and prognosis. Eye 2: 641–645
Kanski JJ (1990) Uveitis in juvenile chronic arthritis. Clin Exp Rheumatol 8: 499–503
Kanski JJ (1992) Lensectomy for complicated cataract in juvenile chronic iridocyclitis. Br J Ophthalmol 76: 72–75
Kenawy N, Clearny G, Mewar D, et al. (2011) Abatacept: a potential therapy in refractory cases of juvenile idiopathic arthritis-associated uveitis. Graefe Arch Clin Exp Ophthalmol 249: 297–300
Kilmartin DJ, Forrester JV, Dick AD (1998) Cyclosporin A therapy in refractory non-infectious childhood uveitis. Br J Ophthalmol 82: 737–742
Kimura SJ, Hogan MJ (1964) Uveitis in Children: Analysis of 274 Cases. Trans Am Ophthalmol Soc 62: 173–192
Kimura SJ, Hogan MJ et al. (1954) Uveitis in children. AMA Am J Dis Child 87: 40–48
Kotaniemi K, Kaipiainen-Seppanen O et al. (1999) A population-based study on uveitis in juvenile rheumatoid arthritis. Clin Exp Rheumatol 17: 119–122
Kotaniemi K, Kautiainen H et al. (2001) Occurrence of uveitis in recently diagnosed juvenile chronic arthritis: A prospective study. Ophthalmology 108: 2071–2075
Kotaniemi K & Penttila H (2006) Intraocular lens implantation in patients with juvenile idiopathic arthritis-associated uveitis. Ophthalmic Res 38: 318–323
Kotaniemi K, Säilä H, Kautiainen H (2011) Long-term efficacy of adalimumab in the treatment of uveitis associated with juvenile idiopathic arthritis. Clin Ophthalmol 5: 1425–1429
Merriam JC, Chylack LT Jr, Albert DM (1983) Early onset pauciarticular juvenile rheumatoid arthritis: a histopathologic study. Arch Ophthalmol 101: 1085–1092
Mingels A, Hudde T, Heinz C, Heiligenhaus A (2005) Vision threatening complications in uveitis in childhood. Ophthalmologe 105:477–484
Nishihara RM, Skare T, Silva MB, et al. (2009) Antinucleosome antibodies in juvenile chronic arthritis. Clin Rheumatol 28: 1461–1463
Nordal EB, Songstad NT, Berntson L, et al. (2009) Biomarkers of chronic uveitis in juvenile idiopathic arthritis: predictive value of antihistone antibodies and antinuclear antibodies. J Rheumatol 36: 1737–1743
Paivonsalo-Hietanen T, Tuominen J et al. (2000) Uveitis in children: Population-based study in Finland. Acta Ophthalmol Scand 78: 84–88
Parikh JG, Tawansy KA, Rao NA (2008) Immunhistochemical study of chronic nongranulomatous anterior uveitis in juvenile idiopathic arthritis. Ophthalmology 115: 1833–1836
Rabinovich CE (2011) Treatment of juvenile idiopathic arthritis-associated uveitis: challenges and update. Curr Opin Rheumatol 23: 432–436
Reiff A, Takei S et al. (2001) Etanercept therapy in children with treatment- resistant uveitis. Arthritis Rheum 44: 1411–1415
Sabates R, Smith T, Apple D (1979) Ocular histopathology in juvenile rheumatoid arthritis. Ann Ophthalmol 11: 733–737
Samson CM, Waheed N et al. (2001) Methotrexate therapy for chronic noninfectious uveitis. Analysis of a case series of 160 patients. Ophthalmology 108: 1134–1139
Saurenmann RK, Levin AV, Feldman BM et al. (2006) Risk of new-onset uveitis in patients with juvenile idiopathic arthritis treated with anti-TNFalpha agents. J Pediatr 149:833–836
Saurenmann RK, Levin AV, Rose JB et al. (2006) Tumour necrosis factor alpha inhibitors in the treatment of childhood uveitis. Rheumatology (Oxford) 45:982–989
Saurenmann RK, Levin AV, Feldman BM, et al. (2010) Risk factors for development of uveitis differ between girls and boys with juvenile idiopathic arthritis. Arthritis Rheum 62: 1824–1828
Simonini G, Taddio A, Cattalini M, et al. (2011) Prevention of flare recurrences in childhood-refractory chronic uveitis: an open-label comparative study of adalimumab versus infliximab. Arthritis Care Res 63: 612–618
Smith JR, Levinson RD et al. (2001) Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease. Arthritis Rheum 45: 252–257
Subauste CS, Ajzenberg D, Kijlstra A (2011) Review of the series »disease of the year 2011: toxoplamosis« pathophysiology og toxoplasmosis. Ocul Immunol Inflamm 19: 297–306
Suhler EB, Smith JR et al. (2005) A prospective trial of infliximab therapy in patients with refractory uveitis. Trials and tribulations, successes and setbacks. Invest Ophthalmol Vis Sci 46(Suppl): S2387
Tappeiner C, Roesel M et al. (2009) Limited value of cyclosporine A for the treatment of patients with uveitis associated with juvenile idiopathic arthritis. Eye 23:1192–1198
Tappeiner C, Heinz C, Rösel M, Heiligenhaus A (2011) Elevated laser flare values correlate with complicated course of anterior uveitis in patients with juvenile idiopathic arthritis. Acta Ophthalmol 89: e521–521
Tappeiner C, Heinz C, Ganser G, Heiligenhaus A (2012) Is tocilizumab an effective option for treatment of refractory uveitis associated with juvenile idiopathic arthritis? J Rheumatol 39(6):1294–5
Thorne JE, Woreta FA, Dunn JP et al. (2010) Risk of cataract development among children with juvenile idiopathic arthritis-related uveitis treated with topical corticosteroids. Ophthalmology 117: 1436–1441
Tugal-Tutkun I, Havrlikova K et al. (1996) Changing patterns in uveitis of childhood. Ophthalmology 103: 375–383
Tynjälä P, Lindahl P, Honkanen Vet al. (2007) Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis. Ann Rheum Dis 66:548–550
Tynjälä P, Kotaniemi K, Lindahl P et al. (2008) Adalimumab in juvenile idiopathic arthritis-associated chronic anterior uveitis. Rheumatology (Oxford) 47:339–344
Verjans MGM, Heiligenhaus A (2011) Herpes simplex virus-induced ocular disease: detrimental interaction between virus and host. Curr Immunol Rev 7: 310–327
Wittmer R (1987) Juvenile Uveitis. Klin Monatsbl Augenheilk 191:332–333
Wolf MD, Lichter PR et al. (1987) Prognostic factors in the uveitis of juvenile rheumatoid arthritis. Ophthalmology 94: 1242–1248
Zulian F, Martini G et al. (2002) Early predictors of severe course of uveitis in oligoarticular juvenile idiopathic arthritis. J Rheumatol 29: 2446–2453
Zulian F, Balzarin M, Falcini F, et al. (2010) Abatacept for severe anti-tumour necrosis factor alpha refractory juvenile idiopathic arthritisrelated uveitis. Arthritis Care Res 82: 821–825
Literatur zu Kap. 4.10
Ahmed SF, Farquharson C (2010) The effect of GH and IGF1 on linear growth and skeletal development and their modulation by SOCS proteins. J Endocrinol 206:249–259
Aitman TJ, Palmer RG, Loftus J et al. (1989) Serum IGF-I levels and growth failure in juvenile chronic arthritis. Clin Exp Rheumatol 7: 557–561
Bechtold S, Ripperger P, Dalla Pozza R et al. (2007) Growth hormone increases final height in patients with juvenile idiopathic arthritis: data from a randomized controlled study. J Clin Endocrinol Metab 92:3013–8
Bechtold S, Ripperger P, Mühlbayer D et al. (2001) Growth hormone therapy in juvenile rheumatoid arthritis: results of a two-year controlled study on growth and bone. J Clin Endocrinol Metab 86:5737–5744
Berthold HK, Diehl IJ, Gouni-Berthold I (2004) »Phossy jaw« revisited – do bisphosphonates cause »bisphossy jaws«. Drug Safety 27: 920
Billiau AD, Loop M, Le PQ et al. (2010) Etanercept improves linear growth and bone mass acquisition in MTX-resistant polyarticularcourse juvenile idiopathic arthritis. Rheumatology 49: 1550–1558
Bianchi ML, Cimaz R, Galbiati E, Corona F, Cherubini R, Bardare M (1999) Bone mass change during methotrexate treatment in patients with juvenile rheumatoid arthritis. Osteoporosis Int 10: 20–25
Bischoff HA, Borchers M, Gudat F (2001) In situ detection of 1,25-dihydroxyvitamin D3 receptor in human skeletal muscle tissue. Histochem J 33: 19–24
Consensus Development Conference (1993) Diagnosis, prophylaxis and treatment of osteoporosis. Am J Med 94: 646–650
Cimaz R, Rusconi R, Cesana B et al. A multicenter study on insulin-like growth factor-I serum levels in children with chronic inflammatory disease. Clin Exp Rheumatol 1997; 15: 691–696
Cooper DM, Nemet D, Galassetti P (2004) Exercise, stress, and inflammation in the growing child: from the bench to the playground. Curr Opin Pediatr 16: 286–292
De Benedetti F, Alonzi T, Moretta A et al. (1997) Interleukin 6 causes growth impairment in transgenic mice through a decrease in insulin- like growth factor one. J Clin Invest 99: 643–650
De Benedetti F, Meazza C, Olivieri M et al. (2001) Effect of IL-6 on IGF binding protein-3: a study in IL-6 transgenic mice and in patients with systemic juvenile idiopathic arthritis. Endocrinology 142: 4818–4826
De Jong Z, Munneke M, Lems WF, Zwinderman AH, Kroon HM, Pauwels EK, Jansen A, Ronday KH, Dijkmans BA, Breedveld FC, Vliet Vlieland TP, Hazes JM (2004) Slowing of bone loss in patients with rheumatoid arthritis by long-term high-intensity exercise: results of a randomized, controlled trial. Arthritis Rheum 50: 1066–1076
Delharty PJD (1998) Interleukin-1 ß suppress growth hormone-induced acid-labile subunit mRNA levels and secretion in primary hepatocytes. Biochem Biophys Res Commun 243: 269–272
Elsasser U, Wilkins B, Hesp R, Thurnham DI, Reeve J, Ansell BM (1982) Bone rarefication and crush fractures in juvenile chronic arthritis. Arch Dis Child 57: 377–380
Frost HM, Schoenau E (2000) The »Muscle Bone Unit« in children and adolescents: a 2000 overview. J Ped Endocr Metab 13: 571–590
Giannini EH, Ilowite NT, Lovell DJ et al. (2010) Effects of long-term etanercept treatment on growth in children with selected categories of juvenile idiopathic arthritis. Arthritis Rheum 62: 3259–3264
Grote FK, Van Suijlekom-Smit LW, Mul D et al. (2006) Growth hormone treatment in children with rheumatic disease, corticosteroid induced growth retardation and osteopenia. Arch Dis Child 91: 56–60
Häkkinen A, Sokka T, Kautiainen H, Kotaniemi A, Hannonen P (2004) Sustained maintenance of exercise induced muscle strength gains and normal bone mineral density in patients with early rheumatoid arthritis: a 5 year follow up. Ann Rheum Dis 63: 910–916
Henderson CJ, Cawkwell GD, Specker BL, Sierra RI, Wilmott RW, Campaigne BN, Lovell DJ (1997) Predictors of total body bone mineral density in non-corticosteroid treated prepubertal children with juvenile rheumatoid arthritis. Arthritis Rheum 40: 1967–1975
Henderson CJ, Specker BL, Sierra RI, Campaigne BN, Lovell DJ (2000) Total body bone mineral content in non-corticosteroid treated postpubertal females with juvenile rheumatoid arthritis. Arthritis Rheum 43: 531–540
Hochberg Z, Bereket A, Davenport M, Delemarre-van de Waal HA, De Schepper J, Levine MA, Shaw N, Schoenau E, van Coeverden SC, Weisman Y, Zadik Z (2002) Consensus Development for the supplementation of vitamin D in childhood and adolescence. Horm Res 58: 39–51
Hofbauer LC, Schoppet M (2004) Clinical implications of the osteoprotegerin/ RANKL/RANK system for bone and vascular diseases. JAMA 292: 490–495
Homik J, Cranney A, Shea B, Tugwell P, Wells G, Adachi R, Suarez-Almazor M (2004) Bisphosphonates for steroid induced osteoporosis (Cochrane Review). In: The Cochrane Library, Issue 3. Wiley & Sons, Chichester
Homik J, Suarez-Almazor ME, Shea B, Cranney A, Wells G, Tugwell P (2004) Calcium and Vitamin D for corticosteroid-induced osteoporosis (Cochrane Review). In: The Cochrane Library, Issue 3. Wiley & Sons, Chichester
Kotaniemi A, Savolainen A, Kautiainen H, Kroeger H (1993) Estimation of central osteopenia in children with chronic polyarthritis treated with glucocorticoids. Pediatrics 91: 1127–1130
Kotaniemi A, Savolainen A, Kroger H Kautiainen H, Isomaki H (1998) Development of bone mineral density at the lumbar spine and femoral neck in juvenile chronic arthritis – a prospective one year follow up study. J Rheumatol 25: 2450–2455
Kotaniemi A, Savolainen A, Kroger H Kautiainen H, Isomaki H (1999) Weight-bearing physical activity, calcium intake, systemic glucocorticoids, chronic inflammation ad body constitution as determinants of lumbar and femoral bone mineral in juvenile chronic arthritis. Scand J Rheumatol 28: 19–26
Lien G, Flato B, Haugen M, Vinje O, Sorskaar D, Dale K, Johnston V, Egeland T, Forre O (2003) Frequency of osteopenia in adolescents with early-onset juvenile idiopathic arthritis. Arthritis Rheum 48: 2214–2223
Markula-Patjas KP, Valta HL, Kerttula LI, et al. (2012) Prevalence of vertebral compression fractures and associated factors in children and adolescents with severe juvenile idiopathic arthritis. J Rheumatol 39:365–373
Martensson K, Chrysis D, Sävendahl L (2004) Interleukin-1β and TNF-α act in synergy to inhibit longitudinal growth in fetal rat metatarsal bones. J Bone Miner Res 19: 1805–1812
Mastorakos G, Magiakou AL, Chrousos G (1995) Effects of the immune/ inflammatory reaction on the hypothalamic pituitary adrenal axis. Ann NY Acad Sci 771: 438–448
Minden K (2009) Adult outcomes of patients with juvenile idiopathic arthritis. Horm Res72 Suppl 1:20–5
Munns CF, Rauch F, Ward L, Glorieux FH (2004) Maternal and fetal outcome after long-term pamidronate treatment before conception: a report of two cases. J Bone Miner Res 19: 1742–1745
Murray KJ, Boyle RJ, Woo P (2000) Pathological fractures and osteoporosis in a cohort of 103 systemic onset juvenile idiopathic arthritis patients. Arthritis Rheum 43: S119
Noguera A, Ros JB, Pavia C, Alcover E, Valls C, Villaronga M, Gonzalez E (2003) Bisphosphonates, a new treatment for glucocorticoid-induced osteoporosis in children. J Pediatr Endocrinol Metab 16: 529–526
Padeh S, Pinhas-Hamiel O, Zimmermann-Sloutskis D et al. (2001) Children with oligoarticular juvenile idiopathic arthritis are at considerable risk for growth retardation. J Pediatr 159: 832–837
Pepmueller PH, Cassidy JT, Allen SH, Hillman LS (1996) Bone mineralization and bone mineral metabolism in children with juvenile rheumatoid arthritis. Arthritis Rheum 39: 746–757
Rauch F, Schoenau E (2001) Changes in bone density during childhood and adolescence: an approach based on bone’s biological organisation. J Bone Miner Res 16: 1–8
Reed A, Haugen M, Pachman LM, Langman CB (1991) 25-Hydroxyvitamin D therapy in children with active juvenile rheumatoid arthritis: short term effects on serum osteocalcin levels and bone mineral density. J Pediatrics 119: 657–660
Rodd C, Lang B, Ramsay T, et al. (2012) Incident vertebral fractures among children with rheumatic disorders 12 months after glucocorticoid initiation: a national observational study. Arthritis Care Res (Hoboken) 64:122–131
Roth J, Palm C, Scheunemann I, Ranke MB, Schweizer R, Dannecker GE (2004) Musculoskeletal abnormalities of the forearm in patients with juvenile idiopathic arthritis relate mainly to bone geometry. Arthritis Rheum 50: 1277–1285
Saha MT, Haapasaari J, Hannula S et al. (2004) Growth hormone is effective in the treatment of severe growth retardation in children with juvenile chronic arthritis. Double blind placebo-controlled followup study. J Rheumatol 31: 1413–1417
Schmeling H, Seliger E, Horneff G (2003) Growth reconstitution in juvenile idiopathic arthritis treated with etanercept. Clin Exp Rheumatol 21: 779–784
Schoenau E, Neu CM, Beck B, Manz F, Rauch F (2002) Bone mineral content per muscle cross-sectional area as an index of the functional muscle-bone unit. J Bone Min Res 17: 1095–1101
Schoenau E, Rauch F (1997) Markers of bone and collagen metabolism – problems and perspectives in paediatrics. Horm Res 48 (Suppl 5): 50–59
Schoenau E, Saggese G, Peter F, Baroncelli GI, Shaw NJ, Crabtree NJ, Zadik Z, Neu CM, Noordam C, Radetti G, Hochberg Z (2004) From bone biology to bone analysis. Horm Res 61: 257–269
Simon D, Fernando C, Czernichow P et al. (2002) Linear growth and final height in patients with systemic juvenile idiopathic arthritis treated with long term glucocorticoids. J Rheumatol 29: 1296–1300
Simon D, Prieur AM, Quartier P et al. (2007) Early recombinant human growth hormone treatment in glucocorticoid-treated children with juvenile idiopathic arthritis: a 3-year randomized study. J Clin Endocrinol Metab 92:2567–73
Specker BL, Schoenau E (2005) Quantitative bone analysis in children: current methods and recommendations. J Pediatr 146: 726–731
Srivastava T, Alon US (2003) The role of bisphosphonates in diseases of childhood. Eur J Pediatr 162: 735–751
Tsatsoulis A, Siamopoulou A, Petsoukis CH et al. (1999) Study of growth hormone secretin and action in growth-retarded children with juvenile chronic arthritis (JCA). Growth Hormone & IGF Research 9: 143–149
Tynjälä P, Lahdenne P, Vähäsalo P et al. (2006) Impact of anti-TNF treatment on growth in severe juvenile idiopathic arthritis. Ann Rheum Dis 65: 1044–1049
Schiessl H, Frost HM, Jee WSS (1998) Perspectives: Estrogen and bonemuscle strength and mass relationships. Bone 22: 1–6
Van Staa TP, Cooper C, Leufkens HGM, Bishop N (2003) Children and the risk of fractures caused by oral corticosteroids. J Bone Miner Res 18: 913–918
Wang SJ, Yang YH, Lin YT et al. (2002) Attained adult height in juvenile rheumatoid arthritis with and without corticosteroid treatment. Clin Rheumatol 21: 363–368
Zak M, Müller J, Pedersen FK (1999) Final height, arm span, subischial leg length and body proportions in juvenile chronic arthritis. Horm Res 52: 80–85
Zak M, Hassager C, Lovell DJ, Nielsen S, Henderson CJ, Pedersen FK (1999) Assessment of bone mineral density in adults with a history of juvenile chronic arthritis. Arthritis Rheum 42: 790–798
Literatur zu Kap. 4.11
Adler S, Krivine A, Weix J, Rozenberg F, Launay O, Huesler J, Guillevin L, Villiger PM (2012) Protective effect of A/H1N1 vaccination in immune- mediated disease – a prospectively controlled vaccination study. Rheumatology (Oxford) 51(4):695–700
Aikawa N, Campos L, Goldenstein-Schainberg C, Saad C, Ribeiro A, Bueno C, Precioso A, Timenetsky M, Silva C, Bonfá E (2012) Effective seroconversion and safety following the pandemic influenza vaccination (anti-H1N1) in patients with juvenile idiopathic arthritis. Scand J Rheumatol [Epub ahead of print]
Aikawa NE, Campos LM, Silva CA, Carvalho JF, Saad CG, Trudes G, Duarte A, Miraglia JL, Timenetsky Mdo C, Viana VS, França IL, Bonfa E, Pereira RM (2012) Glucocorticoid: major factor for reduced immunogenicity of 2009 influenza A (H1N1) vaccine in patients with juvenile autoimmune rheumatic disease. J Rheumatol 39(1):167–73
Barbosa CM, Terreri MT, Rosário PO, de Moraes-Pinto MI, Silva CA, Hilário MO (2012) Immune response and tolerability of varicella vaccine in children and adolescents with systemic lupus erythematosus previously exposed to varicella-zoster virus. Clin Exp Rheumatol 30(5):791–8
Beukelman T, Xie F, Chen L, Baddley JW, Delzell E, Grijalva CG, Lewis JD, Ouellet-Hellstrom R, Patkar NM, Saag KG, Winthrop KL, Curtis JR; SABER Collaboration (2012) Rates of hospitalized bacterial infection associated with juvenile idiopathic arthritis and its treatment. Arthritis Rheum 64(8):2773–80
Bingham CO 3rd, Looney RJ, Deodhar A, Halsey N, Greenwald M, Codding C, Trzaskoma B, Martin F, Agarwal S, Kelman A (2010) Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial. Arthritis Rheum 62(1):64–74
Borte S, Liebert UG, Borte M, Sack U (2009) Efficacy of measles, mumps and rubella revaccination in children with juvenile idiopathic arthritis treated with methotrexate and etanercept. Rheumatology (Oxford) 48:144–8
Bracaglia C, Buonuomo PS, Tozzi AE, Pardeo M, Nicolai R, Campana A, Insalaco A, Cortis E, DE Benedetti F (2012) Safety and efficacy of etanercept in a cohort of patients with juvenile idiopathic arthritis under 4 years of age. J Rheumatol 39(6):1287–90
Dell’Era L, Corona F, Daleno C, Scala A, Principi N, Esposito S (2012) Immunogenicity, safety and tolerability of MF59-adjuvanted seasonal influenza vaccine in children with juvenile idiopathic arthritis. Vaccine. 2012 Jan 20;30(5):936–40
Denman EJ, Denman AM, Greenwood BM, Gall D, Heath RB (1970) Failure of cytotoxic drugs to suppress immune responses of patients with rheumatoid arthritis. Ann Rheum Dis 29(3):220–31
Elkayam O, Bashkin A, Mandelboim M, Litinsky I, Comaheshter D, Levartovsky D, Mendelson E, Wigler I, Caspi D, Paran D (2010) The effect of infliximab and timing of vaccination on the humoral response to influenza vaccination in patients with rheumatoid arthritis and ankylosing spondylitis. Semin Arthritis Rheum 39(6):442–7
Empfehlungen der Ständigen Impfkommission (STIKO) am Robert Koch-Institut. Epidemiologisches Bulletin 30. Juli 2012; Nr. 30 (http://www.rki.de)
Erguven M, Kaya B, Hamzah OY, Tufan F (2011) Evaluation of immune response to hepatitis A vaccination and vaccine safety in juvenile idiopathic arthritis. J Chin Med Assoc 74(5):205–8
Farmaki E, Kanakoudi-Tsakalidou F, Spoulou V, Trachana M, Pratsidou- Gertsi P, Tritsoni M, Theodoridou M (2010) The effect of anti-TNF treatment on the immunogenicity and safety of the 7-valent conjugate pneumococcal vaccine in children with juvenile idiopathic arthritis. Vaccine 28(31):5109–13
França IL, Ribeiro AC, Aikawa NE, Saad CG, Moraes JC, Goldstein- Schainberg C, Laurindo IM, Precioso AR, Ishida MA, Sartori AM, Silva CA, Bonfa E (2012) TNF blockers show distinct patterns of immune response to the pandemic influenza A H1N1 vaccine in inflammatory arthritis patients. Rheumatology (Oxford) 51(11): 2091–8
Heijstek MW, Pileggi GC, Zonneveld-Huijssoon E, Armbrust W, Hoppenreijs EP, Uiterwaal CS, Kuis W, Wulffraat NM (2007) Safety of measles, mumps and rubella vaccination in juvenile idiopathic arthritis. Ann Rheum Dis 66(10):1384–7
Heijstek MW, Ott de Bruin LM, Bijl M, Borrow R, van der Klis F, Koné-Paut I, Fasth A, Minden K, Ravelli A, Abinun M, Pileggi GS, Borte M, Wulffraat NM; EULAR (2011a) EULAR recommendations for vaccination in paediatric patients with rheumatic diseases. Ann Rheum Dis 70(10):1704–12
Heijstek MW, Ott de Bruin LM, Borrow R, van der Klis F, Koné-Paut I, Fasth A, Minden K, Ravelli A, Abinun M, Pileggi G, Borte M, Bijl M, Wulffraat NM (2011b) Vaccination in paediatric patients with autoimmune rheumatic diseases: a systemic literature review for the European League against Rheumatism evidence-based recommendations. Autoimmun Rev (2):112–22
Heijstek MW, van Gageldonk PG, Berbers GA, Wulffraat NM (2012) Differences in persistence of measles, mumps, rubella, diphtheria and tetanus antibodies between children with rheumatic disease and healthy controls: a retrospective cross-sectional study. Ann Rheum Dis 71(6):948–54
Höyeraal HM, Mellbye OJ (1974) Humoral immunity in juvenille rheumatoid arthritis. Ann Rheum Dis 33(3):248–54
Kapetanovic MC, Roseman C, Jönsson G, Truedsson L, Saxne T, Geborek P (2011) Antibody response is reduced following vaccination with 7-valent conjugate pneumococcal vaccine in adult methotrexatetreated patients with established arthritis, but not those treated with tumor necrosis factor inhibitors. Arthritis Rheum 63(12):3723–32
Kasapçopur O, Cullu F, Kamburoğlu-Goksel A, Cam H, Akdenizli E, Calýkan S, Sever L, Arýsoy N (2004) Hepatitis B vaccination in children with juvenile idiopathic arthritis. Ann Rheum Dis 63(9):1128–30
Kostinov MP, Tarasova AA, Zaĭtsev EM (2007) [Contents of antibodies to Bordetella pertussis antigens in patients with rheumatic diseases]. Zh Mikrobiol Epidemiol Immunobiol 6:61–4
Malleson PN, Tekano JL, Scheifele DW, Weber JM (1993) Influenza immunization in children with chronic arthritis: a prospective study. J Rheumatol 20(10):1769–73
Minden K, Niewerth M, Borte M, Singendonk W, Haas JP (2007) [Immunization in children and adolescents with rheumatic diseases]. Z Rheumatol 66(2):111–2, 114–8, 120
Miraglia JL, Abdala E, Hoff PM, Luiz AM, Oliveira DS, Saad CG, Laurindo IM, Viso AT, Tayra A, Pierrotti LC, Azevedo LS, Campos LM, Aikawa NE, Timenetsky Mdo C, Luna E, Cardoso MR, Guedes Jda S, Raw I, Kalil J, Precioso AR (2011) Immunogenicity and reactogenicity of 2009 influenza A (H1N1) inactivated monovalent non-adjuvanted vaccine in elderly and immunocompromised patients. PLoS One 6(11):e27214
Mitteilung der Ständigen Impfkommission (STIKO) am Robert Koch- Institut: Hinweise zu Impfungen für Patienten mit Immundefizienz. Epidemiologisches Bulletin 10. November 2005; Nr. 39 (http://www.rki.de)
Mori S, Ueki Y, Hirakata N, Oribe M, Hidaka T, Oishi K (2012) Impact of tocilizumab therapy on antibody response to influenza vaccine in patients with rheumatoid arthritis. Ann Rheum Dis 71(12):2006–10
Morin MP, Quach C, Fortin E, Chédeville G (2012) Vaccination coverage in children with juvenile idiopathic arthritis followed at a paediatric tertiary care centre. Rheumatology (Oxford) 51(11):2046–50
Ogimi C, Tanaka R, Saitoh A, Oh-Ishi T (2011) Immunogenicity of influenza vaccine in children with pediatric rheumatic diseases receiving immunosuppressive agents. Pediatr Infect Dis J 30(3):208–11
Olson NY, Lindsley CB (1994) Influenza immunization in children with chronic arthritis. J Rheumatol 21(8):1581–2
Pileggi GS, de Souza CB, Ferriani VP (2010) Safety and immunogenicity of varicella vaccine in patients with juvenile rheumatic diseases receiving methotrexate and corticosteroids. Arthritis Care Res (Hoboken) 62:1034–9
Quartier P, Allantaz F, Cimaz R, Pillet P, Messiaen C, Bardin C, Bossuyt X, Boutten A, Bienvenu J, Duquesne A, Richer O, Chaussabel D, Mogenet A, Banchereau J, Treluyer JM, Landais P, Pascual V (2011) A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann Rheum Dis 70(5):747–54
Rehnberg M, Brisslert M, Amu S, Zendjanchi K, Håwi G, Bokarewa MI (2010) Vaccination response to protein and carbohydrate antigens in patients with rheumatoid arthritis after rituximab treatment. Arthritis Res Ther 12(3):R111
Ribeiro AC, Laurindo IM, Guedes LK, Saad CG, Moraes JC, Silva CA, Bonfa E (2012) Abatacept severely reduces the immune response to pandemic 2009 influenza A/H1N1 vaccination in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken). [Epub ahead of print]
Shinoki T, Hara R, Kaneko U, Miyamae T, Imagawa T, Mori M, Yokota S (2012) Safety and response to influenza vaccine in patients with systemic-onset juvenile idiopathic arthritis receiving tocilizumab. Mod Rheumatol (6):871–6
Stéphan JL, Koné-Paut I, Galambrun C, Mouy R, Bader-Meunier B, Prieur AM (2001) Reactive haemophagocytic syndrome in children with inflammatory disorders. A retrospective study of 24 patients. Rheumatology (Oxford) 40(11):1285–92
Tam LS, Chan AY, Chan PK, et al. (2004) Increased prevalence of squamous intraepithelial lesions in systemic lupus erythematosus: association with human papillomavirus infection. Arthritis Rheum 50:3619–25
Toplak N, Subelj V, Kveder T, Cucnik S, Prosenc K, Trampus-Bakija A, Todorovski L, Avcin T (2012) Safety and efficacy of influenza vaccination in a prospective longitudinal study of 31 children with juvenile idiopathic arthritis. Clin Exp Rheumatol 30(3):436–44
van Assen S, Agmon-Levin N, Elkayam O, Cervera R, Doran MF, Dougados M, Emery P, Geborek P, Ioannidis JP, Jayne DR, Kallenberg CG, Müller-Ladner U, Shoenfeld Y, Stojanovich L, Valesini G, Wulffraat NM, Bijl M (2011) EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 70(3):414–22
van Assen S, Holvast A, Benne CA, Posthumus MD, van Leeuwen MA, Voskuyl AE, Blom M, Risselada AP, de Haan A, Westra J, Kallenberg CG, Bijl M (2010) Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab. Arthritis Rheum 62(1):75–81
Zonneveld-Huijssoon E, Ronaghy A, Van Rossum MA, Rijkers GT, van der Klis FR, Sanders EA, Vermeer-De Bondt PE, Hoes AW, van der Net JJ, Engels C, Kuis W, Prakken BJ, Van Tol MJ, Wulffraat NM (2007) Safety and efficacy of meningococcal c vaccination in juvenile idiopathic arthritis. Arthritis Rheum 56:639–646
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Minden, K. et al. (2014). Juvenile idiopathische Arthritis. In: Wagner, N., Dannecker, G. (eds) Pädiatrische Rheumatologie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-34728-3_4
Download citation
DOI: https://doi.org/10.1007/978-3-642-34728-3_4
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-34727-6
Online ISBN: 978-3-642-34728-3
eBook Packages: Medicine (German Language)